

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Le, TG;Kundu, A;Ghoshal, A;Nguyen, NH;Preston, S;Jiao, Y;Ruan, B;Xue, L;Huang, F;Keiser, J;Hofmann, A;Chang, BCH;Garcia-Bustos, J;Jabbar, A;Wells, TNC;Palmer, MJ;Gasser, RB;Baell, JB

Title:

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

Date:

2018-12-13

Citation:

Le, T. G., Kundu, A., Ghoshal, A., Nguyen, N. H., Preston, S., Jiao, Y., Ruan, B., Xue, L., Huang, F., Keiser, J., Hofmann, A., Chang, B. C. H., Garcia-Bustos, J., Jabbar, A., Wells, T. N. C., Palmer, M. J., Gasser, R. B. & Baell, J. B. (2018). Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm. *Journal of Medicinal Chemistry*, 61 (23), pp.10875-10894. <https://doi.org/10.1021/acs.jmedchem.8b01544>.

Persistent Link:

<https://hdl.handle.net/11343/303741>

Optimization of Novel 1-Methyl-1*H*-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

Thuy G. Le,[‡] Abhijit Kundu,[§] Atanu Ghoshal,[§] Nghi H. Nguyen,[‡] Sarah Preston,^{‡,◇} Yaqing Jiao,[‡] Banfeng Ruan,^{‡,‡} Lian Xue,[‡] Fei Huang,[‡] Jennifer Keiser,^{‡,◇} Andreas Hofmann,^{‡,◇} Bill C. H. Chang,[‡] Jose Garcia-Bustos,[‡] Abdul Jabbar,[‡] Timothy N. C. Wells,[‡] Michael J. Palmer,[‡] Robin B. Gasser,^{‡,‡} and Jonathan B. Baell^{‡,‡,‡,‡}

[‡]School of Pharmaceutical Sciences, Nanjing Tech University, No. 30 South Puzhu Road, Nanjing 211816, People's Republic of China

[‡]Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

[§]TCG Lifesciences Private Limited, Block BN, Plot 7, Salt-lake Electronics Complex, Sector V, Kolkata 700091, West Bengal, India

[‡]Griffith Institute for Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia

[‡]Department of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria 3010, Australia

[‡]School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, People's Republic of China

[‡]Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland


[‡]University of Basel, 4001 Basel, Switzerland

[‡]Medicines for Malaria Venture, 1215 Geneva, Switzerland

[‡]School of Health and Life Sciences, Federation University, Ballarat, Victoria 3353, Australia

Supporting Information

ABSTRACT: A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode *Haemonchus contortus* led to the identification of a 1-methyl-1*H*-pyrazole-5-carboxamide derivative with an IC_{50} of 0.29 μ M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure–activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound **60** was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC_{50} of 0.01 μ M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 μ M.



INTRODUCTION

Parasitic worms (helminths) are major causes of diseases of humans, other animals, and plants worldwide.¹ Besides the socioeconomic impact on humans, parasitic helminths of livestock animals cause substantial productivity losses, reaching billions of dollars per annum.² For instance, gastrointestinal roundworms (nematodes) are the main cause of reduced weight gain, weight loss, poor meat and milk production, and mortality in farm animals. In this context, nematodes of the order Strongylida are of paramount importance as pathogens,² and in particular the barber's pole worm *Haemonchus contortus*

(*H. contortus*) represents this order and is one of the most pathogenic members, affecting hundreds of millions of small ruminants (including sheep and goats) worldwide.^{2,3}

The control of *H. contortus* and other strongylid nematodes has relied heavily on the treatment of ruminants with a small number of anthelmintic drugs. These broad-spectrum anthelmintics work mainly by inhibiting muscle contraction, leading to a paralysis of nematodes or via the disruption of

Received: October 10, 2018

Published: November 7, 2018





Figure 1. Some current anthelmintic drugs used to treat nematodiasis of livestock animals.

Scheme 1^a



^a(a) Pd(dppf)Cl₂, K₂CO₃, dioxane/H₂O, 110 °C or Pd(PPh₃)₄, toluene, 80 °C; (b) LiAlH₄, THF; (c) HOAt, EDCI, ACN, 80 °C or HATU, DIPEA, DMF or T₃P, DIPEA, THF.

microtubule function.⁴ The excessive and uncontrolled use of these anthelmintics has provoked the development of drug resistant worms.^{5,6} The two newer groups of anthelmintics, namely amino-acetonitrile derivatives (e.g., monepantel) and derquantel (Figure 1), have been effective at combating multiresistant nematodes, but emerging resistance is proving problematic.^{7–10} Recent reports disclose selenophene and thiophene derivatives, acrylonitrile-based compounds, and 2-phenylimidazo[1,2-*b*]pyridazine derivatives, each with potent in vitro activity against *H. contortus*, but drug development has yet to be undertaken.^{11–13} Thus, given the expansion of resistance to existing anthelmintics, the search for new chemical entities with nematocidal or nematostatic activity remains crucial.


Our ultimate goal is to discover an orally administered anthelmintic for livestock. With this focus in mind, our team established a phenotypic screening platform¹⁴ that assesses the motility and development of parasitic larvae of *H. contortus*; the use of this platform has yielded a number of compounds with anthelmintic activity in vitro.^{13–18} For instance, we have screened the “Pathogen Box” (www.pathogenbox.org) from the Medicines for Malaria Venture (MMV; www.mmv.org) to discover that the approved pesticide, tolfenpyrad, possesses potent anthelmintic activity against *H. contortus*.¹⁶ We also screened a high quality, diverse library of ~13500 synthetic small molecules to discover a proline derivative with similarly interesting anthelmintic activity.¹⁸ From the latter screen, we also identified a 1-methyl-1*H*-pyrazole-5-carboxamide hit, designated SN00799639 (**1**), which we have not yet reported on. Here, we describe medicinal chemistry optimization and elucidation of the structure–activity relationship (SAR) for **1**, iteratively guided by results from our phenotypic assay for *H. contortus*.

RESULTS AND DISCUSSION

The construction of the LHS, middle section, and RHS of the scaffold is depicted in Scheme 1. For late-stage RHS derivatization, from Scheme 1, the thiazole halide building block for the LHS was subjected to a Suzuki coupling reaction for a C–C bond formation with the middle ring section harboring a nitrile group, which was subsequently reduced to give the free amine that served as the precursor for subsequent RHS amide coupling reaction. The same synthetic principle was applied when varying LHS or middle section.

To examine SAR, compounds were first subjected to a primary biological assay that assessed the motility of *H. contortus* at the exsheathed L3 (xL3) stage, using monepantel and moxidectin as positive control anthelmintics. Only compounds that resulted in ≥70% motility inhibition of xL3 larvae at 100 μM concentration were then subjected to subsequent dose–response experiments to obtain IC₅₀ values and then further assessed in the L4 development assay.

Prior to the synthesis of carboxamide derivatives, initial mining of the high throughput deck for analogues led to the purchase and screening of broadly related analogues, but none of them were active (see Supporting Information). A set of analogues with closely related structures of **1** was also obtained from commercial sources to assess SAR; results are summarized in Table 1. This set mainly probed the substitution pattern of the RHS pyrazole, and the results clearly indicate the importance of the 1-alkyl group, which was crucial to maintain activity against *H. contortus*, as neither the *des*-alkyl pyrazole nor the 2-alkyl pyrazole were tolerated (4–7). Replacing the ethyl group on the LHS thiazole with either a methyl (**2**) or *iso*-propyl (**3**) group had minor effects, and resulted in comparable IC₅₀ values of 10.7 and 12.0 μM, respectively. In relation to the measured cytotoxicity, the methyl substituents on the thiazole ring exerted only 1%

Table 1. SAR of Commercially Resourced Compounds Closely Related to the Initial Hit Compound 1**1 to 7**

entry ^a	R	R'	IC ₅₀ (μM) ± SD in xL3 motility assay	IC ₅₀ (μM) ± SD in L4 development assay	MCF10A cytotoxicity (%) ^b
1	Et	1-Me	8.40 ± 1.40	0.29 ± 0.10	24.4
2	Me	1-Me	10.7 ± 5.43	0.37 ± 0.13	1
3	iso-prop	1-Me	12.0 ± 3.38	0.33 ± 0.16	44
4	Et	2-Me	>100		
5	Et	2-Et	>100		
6	Me	2-Et	>100		
7	Me	1-H	>100		

^aCompounds purchased from ChemDiv (www.chemdiv.com).^bInhibition at 50 μM.

inhibition of mammal epithelial cell viability at 50 μM. Therefore, thiazole with the methyl substituent from 2 was considered as interchangeable with the original thiazole from 1 in this SAR study.

Tight SAR was observed from the diverse modifications on the RHS pyrazole (Table 2). To first explore the chemical space of the 1-position of the pyrazole, the methyl group was replaced with ethyl and *iso*-propyl to produce analogues 8 and 9, respectively. However, this replacement led to a complete loss of activity. For the 3-position of the pyrazole, we experimented with electron withdrawing groups, such as CF₃ and CN, as seen for analogues 10 and 11; however, none of these groups was active. In contrast, when adding an ethyl group also at the 3-position to give 12, activity against both xL3 motility and L4 development was regained. When CF₃ and CN groups were each probed at the 4-position of the pyrazole (compounds 13 and 14), activity could not be retained. A 4-F substituent gave rise to analogue 15, exhibited comparable activity to the original hit 1, in terms of inhibition of both xL3 motility and L4 development. Similar to the observation with 1, compound 15 had low cytotoxicity (<25%) against mammal epithelial cell proliferation when tested at a concentration of 50 μM. Interestingly, when Cl in place of F was probed at the same position (16), activity against xL3 motility was completely lost. Although having an additional CF₃ group at the 3-position (17) did not retrieve any activity, activity was “recovered” when the methoxy group was evaluated (18). A bulky aliphatic group, such as cyclopentane (19), was not tolerated. In summary, among the substituents explored for position 4, a fluoro in the 4-position of the pyrazole group was regarded as the most favored.

To explore SAR of the LHS of the scaffold (Table 3), we first probed different substitutions of the thiazole, such as the *des*-methyl analogue (20), 4,5-dimethyl (21), benzothiazole (22), or the regioisomer 23, as well as a methylene insertion between the middle phenyl ring section and the thiazole (compound 24). However, none of these analogues affected *H. contortus* xL3 motility or L4 development. The incorporation of hydrophobic electron-withdrawing species to the thiazole ring, such as 4-Cl (compound 25) or fluoroalkyl (26–

28), resulted in moderate inhibitory activity on L4 development, with IC₅₀ values ranging from 0.73 to 3.25 μM. Next, we investigated other 5-membered ring isosteres of the thiazole, such as the substituted imidazole 29, pyrazoles 30 and 31, triazoles 32–34, and oxazoles 35 and 36. Of these compounds, 31 displayed moderate activity, while the rest were completely inactive. In contrast, potent activity was observed with a set of oxadiazoles (37–39). For the 1,2,4-oxadiazole 37, an IC₅₀ value of 0.18 μM was observed for the inhibition of L4 development, which was a clear improvement from the original hit 1. The regioisomeric 1,2,4-oxadiazole 38 was also quite potent, with an IC₅₀ value of 0.69 μM for inhibition of L4 development. Interestingly, the 1,3,4-oxadiazole 39 was inactive. In addition to 5-membered rings, we also explored 6-membered rings such as pyridine, pyridazine, and pyrazine (40–42), but did not observe any activity with those. Overall, from the investigation of the LHS SAR, and in light of the observed selectivity toward *H. contortus* over mammalian cells, the 1,2,4-oxadiazole moiety was considered the best LHS scaffold.

The SAR for the middle section of 1 was probed next, and the results are shown in Table 4. On the 2-position of the ring, the F substituent (43) displayed moderate activity against both xL3 motility and L4 development, while substituents such as the methoxy (44), methyl (45), or pyridinyl group (46) all led to a total loss of activity against xL3 motility. The same set of substituents, when investigated at the 3-position of the ring, produced similar results in terms of activity, such that the 3-F substituent (47) maintained the original activity against L4 development, while the analogues 48–50 were inactive. Methylation or cyanation of the benzylic carbon (51 and 52, as racemic mixtures) also resulted in inactivity.

Following our discovery of novel oxadiazoles 37 and 38, we set out to combine all determined favorable groups of the RHS and middle section, as well as to modify the alkyl substituent of the oxadiazole (Table 5). Replacing the ethyl group of the oxadiazole with either methyl, *n*-propyl, or fluoroalkyl groups led to a slight loss of xL3 motility and L4 development inhibition compared with the parent oxadiazoles (compounds 53, 54, 57, 58, and 59). Substituents such as *iso*-propyl or *cyclo*-propyl (compounds 55 and 56) modestly improved the activity of the original oxadiazole 37. By retaining the ethyl group of the oxadiazole and incorporating the favorable 4-fluoropyrazole on the RHS, we observed a 10-fold improvement in L4 development inhibitory activity for 60, and 2-fold improvement for 61, compared with 37 and 38, respectively. Not only was a significant improvement observed, these compounds also displayed a further reduction in cytotoxicity compared with 37 and 38. When probing the reverse amide 62, no activity was observed. This result might suggest that a specific orientation of the amide moiety is required for binding to the target. Retaining the 4-fluoropyrazole RHS and replacing the middle phenyl ring with the favored fluoro-substituted ring afforded 63 and 64. Neither of those compounds showed an activity at the order of that observed for 60, but rather has activities at the level of the parent oxadiazole 37.

Clearly, the potent activity established for the optimized oxadiazole 60 indicates a successful additive SAR, which typically suggests specific target engagement. However, we also note that interpretation of SAR in cell-based phenotypic assays may be influenced by factors such as differences in serum protein binding, permeability, and/or efflux mechanisms and

Table 2. SAR of the RHS Pyrazole^a

8 to 19

Entry	R	R'	IC ₅₀ (μM) ± SD in xL3 motility assay	IC ₅₀ (μM) ± SD in L4 development assay	MCF10A Cytotoxicity ^a
8	Me		>100		
9	Me		>100		
10	Et		>100		
11	Et		>100		
12	Me		27.70 ± 18.75	0.71 ± 0.29	26.9%
13	Et		>100		
14	Et		>100		
15	Me		14.50 ± 1.22	0.53 ± 0.24	21.7%
16	Me		>100		
17	Et		>100		
18	Me		24.7 ± 17.9	0.24 ± 0.12	N/A ^b
19	Me		>100		


^aInhibition at 50 μM. ^bNot assessed.

therefore cannot be entirely exclude other contributions to the observed SAR. Despite this, we have observed sharp positive and negative SAR throughout the evaluation of this compound series. These latter observations agree with the notion of specific target engagement. This might be attributable to the nature of the SAR set, which is dominated by heterocyclic interchange rather than gross changes in hydrogen-bond donating properties, lipophilicity, and polarity, such that factors outside specific target engagement are relatively similar across the compound series.















As a representative of the newly discovered bioactive 1,2,4-oxadiazole moiety, compound 37 was subjected to testing in motility assays against a panel of different parasitic nematodes at various concentrations (Table 6). This panel included

Heligiosomoides polygyrus, a rodent nematode which is related to *H. contortus*,¹⁹ *Ancylostoma ceylanicum*, commonly known as hookworm, also related to *H. contortus*, and *Trichuris muris*, commonly known as whipworm, belonging to the adenophorean nematodes. From the results summarized in Table 6, it can be seen that 37 exerted 100% inhibition on *H. polygyrus* adults at the concentration of 10 μM and both third-stage larvae (L3s) of *A. ceylanicum* and first-stage larvae (L1s) of *T. muris* at 100 μM. When tested at 1 μM on *H. polygyrus* adults, at 100 μM on *H. polygyrus* L3s, and at 10 μM on *A. ceylanicum* L3s, compound 37 displayed >80% inhibition. These promising results suggested that the oxadiazole scaffold could be a medium to broad-spectrum nematocidal or nematostatic scaffold.

Table 3. SAR of the LHS Region^a




20 to 42

Entry	R	IC ₅₀ (μM) ± SD in xL3 motility assay	IC ₅₀ (μM) ± SD in L4 development assay	MCF10A Cytotoxicity ^a
20		>100		
21		>100		
22		>100		
23		>100		
24		>100		
25		65.3 ± 13.2	3.25 ± 1.27	34.8%
26		50 ± 0.00	3.27 ± 2.01	22.5%
27		14.3 ± 5.40	0.73 ± 0.23	29%
28		23.7 ± 1.48	1.50 ± 0.56	31.1%
29		>100		
30		>100		
31		28.5 ± 4.95	4.87 ± 0.51	23.5%
32		>100		
33		>100		
34		>100		
35		>100		
36		>100		
37		5.53 ± 4.10	0.18 ± 0.04	21%
38		16.5 ± 10.64	0.69 ± 0.38	25.5%
39		>100		
40		>100		
41		>100		
42		>100		

^aInhibition at 50 μM.

Table 4. SAR of the Middle Section



entry	R	IC ₅₀ (μM) ± SD in xL3 motility assay	IC ₅₀ (μM) ± SD in L4 development assay	MCF10A cytotoxicity ^a (%)
43	2-F	39.5 ± 21.9	1.8 ± 0.001	29.8
44	2-OCH ₃	>100		
45	2-Me	>100		
46	2-pyridinyl	>100		
47	3-F	22.1 ± 3.05	0.24 ± 0.20	27.5
48	3-OCH ₃	>100		
49	3-Me	>100		
50	3-pyridinyl	>100		
51	Me	>100		
52	CN	>100		

^aInhibition at 50 μM.

To assess the drug-likeness of this 1-methyl-1*H*-pyrazole-5-carboxamide series, we evaluated various physicochemical and metabolic parameters for the original hit **1**, as well as the two oxadiazoles **37** and **38**. The results are summarized in Table 7 and show that moving from the initial thiazole to oxadiazole did not markedly affect the molecular weight (MW) and cLogD; both values are within Lipinski's rule-of-five²⁰ for bioavailable compounds. The polar surface area (PSA) increased slightly, but still remains well within limits preferred for optimum cellular permeability and oral bioavailability of drug candidates.²¹ In addition, compound **37** exhibited a 2-fold improved aqueous solubility at pH 2.0 and 4-fold at pH 6.5, while **38** exhibited a 2-fold improvement at pH 6.5. The greatly reduced microsomal degradation, going from the original thiazole to oxadiazole, resulted in longer microsomal half-lives, ranging from 37 to 73 min. All three compounds (**1**, **37**, and **38**) displayed an intermediate predicted hepatic clearance.

CONCLUSIONS

In the search for novel anthelmintics, we developed a compound set based on hit compound **1** which was discovered in a high-throughput screening of proline derivatives using the *H. contortus* motility assay. The novel series of 1-methyl-1*H*-pyrazole-5-carboxamide derivatives reported here resulted from a variety of modifications made to the original screening hit **1** with the goal of improving potency and establishing SAR. Members of this compound series show promise as inhibitors of the development of the parasitic nematode *H. contortus* in vitro and yielded a very tight SAR. The novel 1,2,4-oxadiazole **60** exhibited a remarkable improvement in the inhibition of L4 development, achieving an IC₅₀ value of 10 nM. A hallmark of this chemotype is its very low in vitro toxicity when tested in a mammalian epithelial cell type. Current efforts are directed toward progressing the best compounds to the next stages of drug discovery.

EXPERIMENTAL SECTION

Nematode Assays. *H. contortus* xL3 Motility and L4 Development Assays. Analogues of SN00799639 were screened first at a





concentration of 100 μM against exsheathed third-stage larvae (xL3s) of *H. contortus* in 96-well microculture plates (catalogue no. 3635; Corning 3650, Life Sciences, USA) using relevant control compounds (i.e., moxidectin and monepantel).¹⁵ In brief, compounds were dissolved to a stock concentration of 10 mM in dimethyl sulfoxide (DMSO; catalogue no. 2225; Ajax Finechem, Australia). Using these stock solutions, compounds were then individually diluted to a final concentration of 100 μM into Luria–Bertani medium (LB) supplemented with 100 IU/mL of penicillin, 100 μg/mL of streptomycin, and 2.5 μg/mL of amphotericin (LB*). Compounds were dispensed (in triplicate) into wells of a 96-well microculture plate using a multichannel pipet. In addition, the negative controls (LB*, LB* + 0.5% solvent; six wells each), and positive controls (20 μM of monepantel, Zolvix, Novartis Animal Health, Switzerland; 20 μM of moxidectin, Cydectin, Virbac, France; triplicate wells) and xL3s (~300/well) were dispensed into wells of the plate using an automated multichannel pipet (Viaflo Assist/II, Integra Biosciences, Switzerland). After incubation at 38 °C and 10% CO₂ for 72 h, a video recording (5 s) was taken of each well of the 96-well microculture plate (containing xL3s) using a grayscale camera (Rolera bolt, Q imaging Scientific Coms, Canada) and a motorized X-Y axis stage (BioPoint 2, Ludl Electronics Products, USA). Individual videos were processed to calculate a motility index (MI) using an algorithm described previously.¹⁴ For compounds with anti-xL3 activity, half-maximum inhibitory concentration (IC₅₀) values estimated from 19-point dose–response curves. Compounds were also tested for their ability to affect the development of xL3s to L4s and IC₅₀ were determined from a 8-point dose response curve.^{14,15} Both assays (xL3 motility and L4 development) were performed at least in duplicates on separate days, three times per assay (three wells for each concentration). Motility index data from each assay were converted to a percentage compared with respect to the negative control (LB* + 0.5% solvent), and IC₅₀ values determined using a variable slope four-parameter equation, constraining the top value to 100% and using a least-squares (ordinary) fit model (v.6 GraphPad Software).

A. ceylanicum L3 Motility Assay. *A. ceylanicum* larvae (L3) were obtained by filtering the faeces from infected hamsters and cultivating the eggs for 9 days in the dark at 24 °C.²² L3s were washed in penicillin and streptomycin-supplemented tap water and kept under refrigeration until used. For each compound, three worms were placed in each well of a 24-well plate, using two wells per compound. Levamisole (50 μM) was used as a positive-control compound. Worms were incubated at 37 °C and 5% v/v CO₂ for 72 h in the presence of 50 μM of each compound, and culture medium, which was composed of Hanks' Balanced Salt Solution (HBSS) supplemented with 10% fetal calf serum, 25 μg/mL of amphotericin B, 100 U/mL of penicillin, and 100 μg/mL of streptomycin. Thereafter, the condition of the worms was microscopically evaluated.

T. muris L1 Motility Assay. For *T. muris*, 40 L1s were placed in each well of a 96-well plate and incubated for 24 h at 37 °C and 5% v/v CO₂ in the presence of 100 μL of RPMI-1640 medium with amphotericin B (12.5 μg/mL), penicillin (500 U/mL), streptomycin (500 μg/mL), and 100 μM of the compound to be tested. Levamisole (100 μM) was used as a positive-control compound. Each compound was tested in duplicate. At 24 h, the total number of L1s per well was counted. The larvae were then stimulated with 100 μL of hot water and motile L1s were counted as described by Keiser et al.²²

H. polygyrus L3 Motility Assay. To screen against *H. polygyrus* L3s, female NMRI mice were infected with 80 *H. polygyrus* L3, and following infection patency, *H. polygyrus* eggs were obtained from infected feces as described.²² Collected eggs were placed on agar and incubated for 9 days at 24 °C (in the dark), to allow the L3 to hatch. To test the compounds, 40 L3s were placed in each well of a 96-well plate. Worms were incubated in the presence of 100 μL of RPMI 1640 medium, supplemented with 0.63 μg/mL amphotericin B, 500 U/mL penicillin, 500 μg/mL streptomycin, and compound (10 or 100 μM) to be tested. Each compound was tested in duplicate. One % DMSO and culture medium and 100 μM levamisole served as a negative and positive controls, respectively. Following incubation for

Table 5. Oxadiazole Refinement SAR^a

 53 to 59				
 60 and 61				
 62				
 63 and 64				
Entry	R	IC ₅₀ (μM) ± SD in xL3 motility assay	IC ₅₀ (μM) ± SD in L4 development assay	MCF10A Cytotoxicity ^a
53		13.9 ± 6.52	0.32 ± 0.04	24%
54		11.3 ± 2.40	0.24 ± 0.05	31%
55		6.80 ± 1.23	0.11 ± 0.02	31.5%
56		5.57 ± 4.12	0.08 ± 0.01	26.4%
57		10.7 ± 7.99	0.2 ± 0.0	28.3%
58		11.1 ± 7.85	0.96 ± 0.03	25%
59		34.5 ± 6.50	0.95 ± 0.85	27%
60		5.67 ± 0.470	0.01 ± 0.01	18%
61		16.5 ± 5.23	0.35 ± 0.04	14%
62		>100		
63	2-F	13.1 ± 8.05	0.1 ± 0.0	N/A ^b
64	3-F	17.4 ± 6.12	0.27 ± 0.11	N/A ^b

^aInhibition at 50 μM. ^bNot assessed.

Table 6. Biological Activity Profile of the 1,2,4-Oxadiazole 37 against a Panel of Select Parasitic Nematodes

entry	<i>H. polygyrus</i> adult (% inhibition)		<i>H. polygyrus</i> L3 (% inhibition)	<i>A. ceylanicum</i> L3 (% inhibition)		<i>T. muris</i> L1 (% inhibition)
	10 μM	1 μM	100 μM	100 μM	10 μM	100 μM
37	100	87.5	92	100	84.2	100

72 h, the total number of L3 larvae per well was counted, the larvae were stimulated with 100 μL of hot water (~80 °C), and the moving L3s were counted.

***H. polygyrus* Adult Motility Assay.** To test compounds on *H. polygyrus* adults, female mice were infected as described above and dissected 2 weeks postinfection to collect adult worms. Three adult worms were placed in each well of a 24-well plate and incubated with culture medium and 50 μM of the test compound in duplicate. Adult worms incubated with medium only, and 50 μM levamisole and ivermectin served as negative and positive controls, respectively.

Table 7. Key Physicochemical Parameters and in Vitro Metabolic Stability of Selected Compounds

entry	MW ^a	PSA ^a (Å ²)	cLogD ^a (pH 7.4)	solubility ^b (μg/mL) pH 2.0	pH 6.5	T _{1/2} (min)	CL _{int} ^c in vitro (μL/min/mg)	predicted E _H ^d
1	326	59.8	2.6	25–50	12.5–25	22	80	0.63
37	311	85.8	2.0	50–100	50–100	37	47	0.50
38	311	85.8	2.0	25–50	25–50	73	24	0.34

^aCalculated using ChemAxon JChem software. ^bKinetic solubility determined by nephelometry (Sol_{PH}). ^cIn vitro intrinsic clearance determined in mouse liver microsomes. ^dPredicted hepatic extraction ratio calculated from in vitro data.

Worms were kept in an incubator at 37 °C and 5% CO₂ for 72 h and, subsequently, microscopically evaluated using a viability scale from 3 to 0 as described previously.²²

Cytotoxicity Assay. Compounds were tested for cytotoxicity on noncancerous ("normal") mammary epithelial cell line (MCF10A) as described by Jiao et al.¹⁸ In brief, MCF10A cells (~700 cells/well) were plated into 384-well, black-walled plates (Corning, New York, USA) using a liquid handling dispenser (BioTek, Vermont, USA). Cells were cultured in DMEM-F12 containing 100 ng/mL cholera toxin (Sigma-Aldrich, St Louis, USA), 20 ng/mL human epidermal growth factor (EGF, Life Technologies, Carlsbad, USA), 10 µg/mL insulin (human; Novo Nordisk Pharmaceuticals Pty Ltd., Bagsværd, Denmark), 5% horse serum (Life Technologies, Australia), and 0.5 µg/mL hydrocortisone (Sigma-Aldrich, St Louis, USA). Following a 24 h incubation (37 °C and 5% CO₂), the growth medium was aspirated and compounds were added starting at 50 µM as well as positive- (monepantel) and negative- (medium ± 0.5% DMSO) controls. Compounds were titrated to generate a 5-point dose-response curve (in quadruplicate) and incubated for a further 48 h. To measure cell proliferation, cells were fixed and stained with 4',6-diamidino-2-phenylindole (DAPI; 1:1000) and individual wells imaged at 10-times magnification, covering 16 fields (~90% of well) using a high content imager (Cellomics Cell Insight Personal Cell Imager, ThermoFisher Scientific, Bartlesville, USA) at a fixed exposure time of 0.12 s. Viable cells were counted using the Target Activation BioApplication within the Cellomics Scan software and normalized to the cell density in wells without compound. Experiments were repeated twice on two different days.

Physicochemical Experimental. Calculated Physicochemical Parameters Using ChemAxon JChem Software. A range of physicochemical properties evaluating drug-likeness and likely oral absorption characteristics were calculated using the ChemAxon chemistry cartridge via JChem for Excel software (version 16.4.11). A brief description of each parameter is provided: MW, molecular weight; PSA_{pH 7.4}, polar surface area, also inversely correlates with membrane permeability; cLogD_{pH 7.4}, distribution coefficient, reflecting the partitioning properties of the ionized molecule at a specific pH.

Kinetic Solubility Estimation using Nephelometry (Sol_{pH}). Compound in DMSO was spiked into either pH 6.5 phosphate buffer or 0.01 M HCl (approximately pH 2.0) with the final DMSO concentration being 1%. After 30 min had elapsed, samples were then analyzed via Nephelometry to determine a solubility range. See Bevan et al.²³

In Vitro Metabolic Stability. Incubation. The metabolic stability assay was performed by incubating each test compound in mouse liver microsomes (XenoTech, lot no. 1510256) at 37 °C and a protein concentration of 0.4 mg/mL. The metabolic reaction was initiated by the addition of an NADPH-regenerating system and quenched at various time points over a 60 min incubation period by the addition of ACN containing diazepam as internal standard. Control samples (containing no NADPH) were included (and quenched at 2, 30, and 60 min) to monitor for potential degradation in the absence of cofactor. Microsomal incubations were performed at a substrate concentration of 0.5 µM.

Data Analysis. Species scaling factors from Ring et al.²⁴ were used to convert the in vitro CL_{int} (µL/min/mg) to an in vivo CL_{int} (mL/min/kg). Hepatic blood clearance and the corresponding hepatic extraction ratio (*E_H*) were calculated using the well stirred model of hepatic extraction in each species, according to the "in vitro *T*_{1/2}" approach described in Obach et al.²⁵ The *E_H* was then used to classify compounds as low (<0.3), intermediate (0.3–0.7), high (0.7–0.95), or very high (>0.95) extraction compounds.

Chemistry Experimental. Experimental Conditions (Exp1). All solvents and reagents were used directly from commercial suppliers unless otherwise stated. TLC analyses were performed on precoated silica gel aluminum-backed plates (Merck 60 F254) and visualized under UV light (254 nm). Purification by column chromatography was based on the methods described by Still et al.²⁶ using SiliaFlash P60 silica gel (40–63 µm). All of the final compounds had purities

greater than 95% based on analytical HPLC, ¹H NMR, and LC-MS. Compound purity was analyzed on an Agilent 1260 Infinity analytical HPLC system with the flow rate of 1 mL/min the following technical information: 1260 degasser, 1260 bin pump, 1260 HiP ALS, 1260 TCC, 1260 DAD. Column used: Zorbax Eclipse Plus C18 rapid resolution 4.6 mm × 100 mm 3.5 µm. Solvent A: 99.9% water, 0.1% TFA. Solvent B: 99.9% ACN, 0.1% TFA. Compounds were analyzed through one of the following methods. Gradient: a gradient of 5–100% solvent B in solvent A over 10 min; hydrophobic, a gradient of 5–80% solvent B in solvent A over 0.6 min, then 80–100% of solvent B in solvent A over 9.4 min; hydrophilic, a gradient of 5–25% of solvent B 8.5 min, then 25–100% solvent B in solvent A over 1.5 min. LC/MSD Chemstation Rev.B.04.03 coupled with Masshunter Easy Access software managed the running and processing of samples. LC-MS [*M* + *H*]⁺ of compounds was analyzed on an AGILENT UHPLC/MS 1260/6120 system with the following technical information. Pump, 1260 Infinity G1312B binary pump; autosampler, 1260 Infinity G1367E 1260 HiP ALS; detector, 1290 Infinity G4212A 1290 DAD. LC conditions: reverse phase HPLC analysis; column, Poroshell 120 EC-C18 3.0 mm × 50 mm 2.7 µm; column temperature, 35 °C; injection volume, 1 µL; flow rate, 1 mL/min. Solvent A, 99.9% water, 0.1% formic acid; solvent B, 99.9% ACN, 0.1% formic acid; gradient, 5–100% of solvent B in solvent A over 3.8 min. Gradient takes 4 min to get to 100% solvent B in solvent A; maintain for 3 min and a further 3 min to get back to the original 5% solvent B in solvent A. MS conditions: ion source, quadrupole; ion mode, API-ES; drying gas temp, 350 °C; capillary voltage (V), 3000 (positive); capillary voltage (V), 3000 (negative); scan range, 100–1000; step size, 0.1 s; acquisition time, 5 min. LC/MSD Chemstation Rev.B.04.03 coupled with Masshunter Easy Access software managed the running and processing of samples. All ¹H NMR, ¹³C NMR, and ¹⁹F NMR of small molecules were performed on the Avance III Nanobay 400 MHz Bruker spectrometer coupled to the BACS 60 automatic sample changer and spectra were processed in MestReNova.²⁷ Chemical shifts (δ, ppm) are reported relative to the solvent peak (CDCl₃, 7.26 [¹H] or 77.16 [¹³C]; DMSO-*d*₆, 2.50 [¹H] or 39.52 [¹³C]). Proton resonances are annotated as chemical shift (δ) in ppm, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), coupling constant (*J*, Hz), and number of protons. Microwave reactions were performed on a CEM discovery fitted with an intelligent explorer unit. The temperature range of the unit is –80 to 300 °C, a pressure range of 0–27 bar, power range of 0–300 W, and no prestirring was required.

Experimental Conditions (Exp2). All of the final compounds had purities greater than 95% based on analytical HPLC, ¹H NMR, and LC-MS. Compound purity was analyzed on an Agilent 1260 Infinity analytical HPLC system with the flow rate of 1 mL/min the following technical information: 1260 degasser, 1260 bin pump, 1260 HiP ALS, 1260 TCC, 1260 DAD. Column used: Zorbax Eclipse Plus C18 rapid resolution 4.6 mm × 100 mm 3.5 µm. Solvent A: 99.9% water, 0.1% TFA. Solvent B: 99.9% ACN, 0.1% TFA. Compounds were analyzed through one of the following methods. Gradient: a gradient of 5–100% solvent B in solvent A over 10 min; hydrophobic, a gradient of 5–80% solvent B in solvent A over 0.6 min, then 80–100% of solvent B in solvent A over 9.4 min; hydrophilic, a gradient of 5–25% of solvent B 8.5 min, then 25–100% solvent B in solvent A over 1.5 min. LC/MSD Chemstation Rev.B.04.03 coupled with Masshunter Easy Access software managed the running and processing of samples. ¹H spectra were recorded at 400.20 and 400.10 on a Bruker Avance II and III spectrometer, using solvents from Merck Laboratories. Chemical shifts (δ, ppm) are reported relative to the solvent peak (CDCl₃, 7.25 [¹H]; DMSO-*d*₆, 2.50 [¹H]). Proton resonances are annotated as chemical shift (δ), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), coupling constant (*J*, Hz), and number of protons. LC-MS analysis was carried out using the following method: 5 min LC-MS was performed on the columns (i) Zorbax Extend C18; column length, 50 mm; internal diameter of column, 4.6 mm; particle size, 5 µm (ii) X-bridge C18; column length, 50 mm; internal diameter of column, 4.6 mm; particle

size, 5 μ m; temperature, 25 °C. API 2000 mass spectrometer from Applied Biosystems Triple quadrupole (Q1 scan) mass spectrometer. Ionization method: electrospray. Polarity: positive ions. Capillary (kV) 5.5, DP(V) 50.00, Entrance potential (V) 10, focusing potential (V) 400, source temperature (°C) 200, ion source Gas1 (Psi) 40, ion source gas 2 (Psi) 50, curtain gas (Psi) 40. Mass range: 100–800 amu, 4500 V (positive mode) 5500 V (negative mode). UV wavelength range (nm): 220–260. Method Shimadzu Prominence with the following HPLC gradient conditions: solvent A, 10 mM NH₄OAc in water; solvent B, acetonitrile. Flow rate: 1.2 mL/min. Mobile phase: from 90% [10 mM NH₄OAc in water] and 10% [CH₃CN] to 70% [10 mM NH₄OAc in water] and 30% [CH₃CN] in 1.5 min, further to 10% [10 mM NH₄OAc in water] and 90% [CH₃CN] in 3.0 min, held this mobile phase composition up to 4.0 min and finally back to initial condition in 5.0 min.

General Procedure A1: Suzuki Coupling Reactions. To a microwave tube equipped with a magnetic stirring bar, halide (1.0 equiv), boronic acid or boronic ester (1.0 equiv), and K₂CO₃ (2 equiv) were dissolved in a 1:4 mixture of H₂O:1,4-dioxane. The mixture was degassed for at least 0.5 h before Pd(dppf)Cl₂ (0.05 equiv) was added. The reaction tube was sealed with a cap and heated in a microwave reactor at 110 °C for 2 h. Upon completion (confirmed TLC and/or LC-MS), EtOAc was added to the reaction tube and the mixture was filtered through a pad of Celite and washed with excess EtOAc. The filtrate was then washed with water then brine. The organic layer was then dried (MgSO₄) and solvent was removed in vacuo to afford crude product which was purified by column chromatography to yield desired product.

General Procedure A2: Suzuki Coupling Reactions. A stirred solution of halide (3.12 mmol) and boronic acid (6.24 mmol) in 1,4-dioxane (8 mL) and water (1 mL) was degassed with argon for 5 min. After that Cs₂CO₃ (7.80 mmol) and Pd(PPh₃)₄ (0.19 mmol) were added. The reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was cooled and diluted with EtOAc. Combined organic layer was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated. The crude was purified by column chromatography to yield desired product.

General Procedure A3: Suzuki Coupling Reactions. To a stirred solution of halide (1.0 equiv) in ACN (15 mL) was added boronic acid (1.0 equiv) followed by aqueous Na₂CO₃ (2.5 equiv) solution. The mixture was degassed for 15 min with N₂, and then Pd(PPh₃)₄ (0.05 equiv) was added. Reaction mixture was heated at 100 °C for 20 h then cooled to room temperature and aqueous layer was extracted with EtOAc. Combined organic layer was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated. Crude mass obtained was purified by column chromatography to yield desired product.

General Procedure A4: Suzuki Coupling Reactions. To a mixture of halide (2.29 mmol) and boronic acid (3.43 mmol) in EtOH (1 mL)/toluene (10 mL)/H₂O (1 mL) was added Na₂CO₃ (4.57 mmol). Reaction mixture was degassed by sparging with argon 15 min before Pd(dppf)Cl₂·CH₂Cl₂ (0.22 mmol) was added. Reaction mixture was heated at 100 °C for 16 h under argon. Reaction mixture was cooled to room temperature and concentrated in vacuo. Residue was diluted with water, and aqueous layer was extracted with EtOAc. Combined organic layer was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. Crude was purified by column chromatography to yield desired product.

General Procedure A5: Suzuki Coupling Reactions. In a sealed tube, a solution of aryl halide (10.93 mmol) and bis(pinacolato)diboron (12.02 mmol) in DMSO (15 mL) was degassed with argon for 10 min. Pd(dppf)Cl₂·DCM (1.09 mmol) and KOAc (37.16 mmol) were then added and again degassed for 10 min. The reaction mixture was stirred at 100 °C for 12 h. Upon completion, the reaction mixture was cooled then extracted with EtOAc. The combined organic layer was washed with water and brine, dried over Na₂SO₄, and concentrated. Crude product was purified by column chromatography to give the desired boronic ester. The resulting boronic ester (0.62 mmol) and halothiazole (0.56

mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was degassed with argon for 10 min. KOAc (0.56 mmol) and PdCl₂(dppf)·DCM (0.057 mmol) were then added to the reaction mixture. The reaction mixture was heated at 100 °C for 16 h, then extracted with EtOAc, washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. Crude product was purified by column chromatography to yield desired product.

General Procedure A6: Suzuki Coupling Reactions. To a microwave tube equipped with a magnetic stirring bar, halide (1.0 equiv), bis(pinacolato)diboron (1.0 equiv), and K₂CO₃ (2 equiv) were dissolved in a 1:4 mixture of H₂O:1,4-dioxane. The mixture was degassed for at least 0.5 h before Pd(dppf)Cl₂ (0.05 equiv) was added. The reaction tube was sealed with a cap and heated in a microwave reactor at 110 °C for 2 h. Upon completion (confirmed TLC and/or LC-MS), EtOAc was added to the reaction tube and the mixture was filtered through a pad of Celite and washed with excess EtOAc. The filtrate was then washed with water then brine. The organic layer was then dried (MgSO₄), and solvent was removed in vacuo to afford crude product which was put through a silica plug to give the desired boronic ester. The resulting boronic ester was then subjected to a Suzuki coupling reaction according to general procedure A1 to yield the desired product.

General Procedure B1: Nitrile Reduction. To a solution of benzonitrile (1.0 equiv) in anhydrous THF (10 mL), LiAlH₄ (3.0 equiv) was slowly added. The reaction was left stirred at room temperature for 2 h. Upon completion (confirmed by TLC and/or LC-MS), reaction mixture was cooled on ice before a solution of 1 M NaOH was added. The slurry mixture was then filtered through a pad of Celite. The filtrate was extracted with EtOAc (3 × 30 mL), and combined organic compound was dried (MgSO₄) and concentrated in vacuo. To the residue after removal of solvent, 15 mL of 4 M HCl in 1,4-dioxane was added. The reaction mixture was left stirred at room temperature overnight. Precipitate of the resulting hydrochloride salt was then filtered, washed with diethyl ether, and then dried in a vacuum oven to yield desired product as a hydrochloride salt.

General Procedure B2: Nitrile Reduction. To a stirred solution of benzonitrile (1.0 equiv) in THF (5.0 mL) was added LiAlH₄ solution (2 M in THF, 2.5 equiv) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 3 h. After that, the reaction mixture was quenched with saturated Na₂SO₄ solution (2.0 mL) at 0 °C and diluted with EtOAc (20 mL). Reaction mixture was filtered through a Celite bed and washed thoroughly with EtOAc. The combined filtrate was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to yield desired product as a free base.

General Procedure B3: Nitrile Reduction. To a stirred solution of benzonitrile (1.0 equiv) in mEtOH (40 mL) at 0 °C was added Boc anhydride (2.0 equiv) and NiCl₂·6H₂O (0.1 equiv). NaBH₄ (7.0 equiv) was then added in small portions over a period of 30 min at 0 °C. The resulting reaction mixture containing black precipitate was allowed to warm to room temperature and left to stir for 12 h. The reaction mixture was diluted with ice–water, and the aqueous layer was extracted with EtOAc. Combined organic layer was washed with aqueous NaHCO₃ solution, water, and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. To the residue after removal of solvent, 5 mL of 4 M HCl in 1,4-dioxane was added. The reaction mixture was left stirred at room temperature overnight. Precipitate of the resulting hydrochloride salt was then filtered, washed with diethyl ether, and then dried in a vacuum oven to yield desired product as a hydrochloride salt.

General Procedure C: Cyanation. A solution of aryl halide (1.0 equiv) in DMF (15 mL) was degassed with argon for 10 minutes. After that, Zn(CN)₂ (1.5 equiv), Xanthphos (0.2 equiv), and Pd₂(dba)₃ (0.1 equiv) were added. Then the reaction mixture was stirred at 110 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with water. The aqueous layer was extracted with EtOAc. Combined organic layer was washed with water, brine, dried over anhydrous Na₂SO₄, and concentrated. Crude compound was purified by column chromatography to yield desired product.

General Procedure D1: Thiazole Ring Cyclization. To a stirred solution of haloketone (1.0 equiv) in EtOH (30 mL), thiourea, or thioamide (1.0–1.5 equiv) was added. The reaction mixture was stirred at reflux until completion (confirmed by TLC). Upon completion, the reaction mixture was cooled to room temperature and diluted with water. Aqueous layer was extracted with EtOAc, washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated to afford desired product which was used in next step without purification.

General Procedure D2: Thiazole Ring Cyclization. A mixture of thiobenzamide (4.63 mmol) and haloketone (4.63 mmol) in EtOH (10 mL) was stirred at 60 °C for 3 h. The reaction mixture was concentrated and the residue obtained was washed with acetone and *n*-pentane to afford an orange solid mass which was mixed with *p*-toluenesulfonic acid (0.46 mmol) in toluene (30 mL) and heated at reflux for 20 h in a Dean–Stark apparatus. After removal of the solvent, the residue was diluted with diethyl ether. The resulting solution was washed with water and brine and dried over anhydrous Na_2SO_4 and concentrated in vacuo. The crude was washed with *n*-pentane to afford the desired product.

General Procedure D3: Thiazole Ring Cyclization. A solution of haloketone (2.78 mmol) and thioamide (2.31 mmol) in ACN (7 mL) was heated at 80 °C overnight in a sealed tube. Upon completion, the reaction mixture was concentrated in vacuo and filtered through a pad of silica gel to give desired product.

General Procedure E1: Sandmeyer Reactions. To a stirred solution of amine (7.8 mmol) in ACN (10 mL) was added BuONO (7.8 mmol) dropwise at 0 °C. Then the reaction mixture was allowed to warm to room temperature and CuBr_2 (7.8 mmol) was added. The reaction mixture was stirred at 100 °C for 4 h. After completion of reaction, reaction mixture was cooled to room temperature and diluted with water. Aqueous layer was extracted with EtOAc, and the combined organic layer was washed with water and brine, and dried over anhydrous Na_2SO_4 and concentrated. The crude was purified by column chromatography to yield desired product.

General Procedure E2: Sandmeyer Reactions. To a suspension of CuBr (6.75 mmol) in ACN (10 mL) was added BuONO (6.75 mmol) at 0 °C. A solution of amine (6.75 mmol) in ACN (10 mL) was added dropwise under N_2 at 0 °C, and the resulting mixture was stirred at 50 °C for 30 min. Upon completion, the reaction mixture was cooled to room temperature and diluted with water. The aqueous layer was extracted with EtOH (3 × 30 mL), and the combined organic layer was washed with saturated NH_4Cl solution, water, and brine, then dried over anhydrous Na_2SO_4 and concentrated in vacuo to give crude product, which was purified by column chromatography to afford desired product.

General Procedure F1: Ester Hydrolysis. To a stirred solution of ester (1.0 equiv) in a 3:1 mixture of THF:H₂O, LiOH·H₂O (2.0 equiv) was added. The reaction mixture was stirred at room temperature for 3 h. Upon completion, THF was removed from reaction mixture. Aqueous layer was neutralized by 1 N HCl and extracted with EtOAc, washed with brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo to afford the desired carboxylic acid without further purification.

General Procedure F2: Ester Hydrolysis. To a solution of ester (1.04 mmol) in EtOH (10 mL) was added NaOH (23.75 mmol). The mixture was stirred at room temperature overnight. The solvent was removed in vacuo to give a white solid, which was redissolved in water and washed with EtOAc (3 × 10 mL). The aqueous was acidified with 1 M HCl to pH ~ 3 and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried (MgSO_4) and solvent was removed in vacuo to give the desired carboxylic acid without further purification.

General Procedure F3: Ester Hydrolysis. To a solution of ester (2.93 mmol) in THF (10 mL) was added LiOH (5.86 mmol). The reaction was left stirred at room temperature overnight. THF was removed in vacuo and water (20 mL) was added, followed by 1 M HCl to pH ~ 1. The aqueous was extracted with EtOAc (2 × 10 mL). Combined organic was washed with brine, dried (MgSO_4), and

concentrated in vacuo to give the desired carboxylic acid without further purification.

General Procedure G1: Amide Coupling. Amine (either as free base or HCl salt, 1.0 equiv), HOAt (2.0 equiv), Et_3N (2.0 equiv), EDCI·HCl (2.0 equiv), and carboxylic acid (2.0 equiv) were dissolved in 3 mL of DMF. Reaction mixture was heated at 80 °C until completion (confirmed by TLC and/or LC-MS). Upon completion, EtOAc was added to the reaction mixture. The organic was washed with water and dried (MgSO_4), and the solvent was removed in vacuo to give the crude product, which was purified by column chromatography to yield desired product.

General Procedure G2: Amide Coupling. To a stirred solution of carboxylic acid (0.54 mmol) in DMF (5.0 mL) was added HATU (0.97 mmol) and DIPEA (1.28 mmol). The solution was stirred for 5 min before amine (0.71 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. After completion the reaction was diluted with EtOAc, washed with water and brine, and then dried over anhydrous Na_2SO_4 . Solvent was then removed in vacuo to give crude product, which was purified by column chromatography to yield desired product.

General Procedure G3: Amide Coupling. To a stirred solution of carboxylic acid (0.99 mmol) in DCM (5 mL) was added Et_3N (2.98 mmol), EDCI·HCl (1.19 mmol), and HOBt (1.19 mmol) at room temperature. After 5 min, amine (1.19 mmol) was then added. The reaction mixture was stirred at room temperature for overnight, then extracted with DCM, washed with saturated NaHCO_3 solution and brine, dried over anhydrous Na_2SO_4 , and concentrated to afford crude product which was purified by column chromatography to yield desired product.

General Procedure G4: Amide Coupling. To a stirred solution of carboxylic acid (1.0 equiv) and amine (1.0 equiv) in THF (5 mL), T_3P (2.0 equiv, 50% in EtOAc) and DIPEA (3.0 equiv) were added. The reaction mixture was stirred at room temperature for 6 h. Upon completion, the reaction mixture was diluted with EtOAc, washed with saturated NaHCO_3 solution, brine, dried over Na_2SO_4 , and concentrated in vacuo to give crude product, which was purified by prep-HPLC to afford desired product.

General Procedure G5: Amide Coupling. To a solution of carboxylic acid (1 equiv) in ACN (0.8 M) was added EDCI·HCl (1.2 equiv) and HOAt (1.2 equiv) at room temperature. The mixture was heated to 50 °C, and after 10 min, amine (1.2 equiv) was added. The mixture was allowed to stir at this temperature overnight. The reaction was then cooled to room temperature and concentrated in vacuo. The residue was partitioned between water and EtOAc. The aqueous layer was further washed with EtOAc (2 × 10 mL). The combined organic layers were dried over MgSO_4 and then loaded directly onto silica. The crude product was purified by silica gel chromatography (Isolera Biotage, 0–50% EtOAc/petroleum benzene). Product-containing fractions were combined and concentrated in vacuo to give the desired product.

General Procedure H: Amidoxime Formation. To a stirred solution of nitrile (1.0 equiv) in EtOH (20 mL) were added K_2CO_3 (2.0 equiv) and $\text{NH}_2\text{OH}\cdot\text{HCl}$ (1.5 equiv). The reaction mixture was stirred at reflux for 16 h. Upon completion, the reaction was diluted with EtOAc, and the organic layer was washed with water and brine, dried over anhydrous Na_2SO_4 , and then concentrated in vacuo to afford the desired amidoxime.

General Procedure I1: Boc Protection. Amine (18.54 mmol) was dissolved in a mixture of 10% aqueous NaOH (25 mL) and EtOH (50 mL). The solution was cooled to 0 °C, and boc-anhydride (20.4 mmol) was added slowly. The reaction mixture was stirred at room temperature for 18 h. Upon completion, EtOH was removed in vacuo and water was added. The aqueous layer was acidified slowly with a saturated solution of citric acid (20 mL). The precipitate formed was filtered and dried in a vacuum oven to yield desired boc-protected amine.

General Procedure I2: Boc Protection. To a stirred solution of amine (1.0 equiv) in DCM (8 mL) was added di-*tert*-butyl-dicarbonate (1.0 equiv) slowly, followed by Et_3N (3.0 equiv). Reaction mixture was stirred at room temperature for 16 h. Upon

completion, reaction mixture was concentrated in vacuo and the residue was diluted with saturated aqueous NaHCO₃ solution. The aqueous layer was extracted with DCM (3 × 10 mL). The combined organic layers were washed with water and brine and dried over anhydrous Na₂SO₄ and concentrated in vacuo. Crude product was purified by column chromatography (20% EtOAc in hexane) to yield desired boc-protected amine.

General Procedure J1: 1,2,4-Oxadiazole Ring Cyclization. To a stirred solution of carboxylic acid (1.0 equiv) in DMF (8 mL) was added HATU (2.5 equiv) and DIPEA (3.0 equiv). The reaction mixture was stirred for 5 min before amidoxime (1.0 equiv) was added. The reaction mixture was stirred at room temperature for 16 h, then refluxed at 110 °C for 16 h. Upon completion, EtOAc was added and organic layer was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo to give crude product, which was purified by column chromatography to yield desired product.

General Procedure J2: 1,2,4-Oxadiazole Ring Cyclization. Amidoxime (1.0 equiv), carboxylic acid (1.0 equiv), HOBt (1.2 equiv), and EDCI-HCl (1.3 equiv) were dissolved in 3 mL of DMF in a microwave tube. The reaction mixture was left stirred at room temperature for 0.5 h, then heated in a microwave reactor at 180 °C for 20 min. EtOAc was then added, and organic the layer was washed with water and brine, dried (MgSO₄), and concentrated in vacuo. The crude product was purified by column chromatography to yield desired product.

General Procedure K: Boc Deprotection. To a stirred solution of Boc-protected amine (1.65 mmol) in 1,4-dioxane (5 mL), 4 M HCl in 1,4-dioxane (5 mL) was added and the reaction mixture was stirred at room temperature for 1 h. Upon completion, the resulting HCl salt precipitate was filtered, washed with diethyl ether, dried in a vacuum oven, and directly taken for the next step.

General Procedure L: Radical Reactions. A stirred solution of methylbenzonitrile (1.0 equiv) in 1,2-dichloroethane (240 mL) was degassed under N₂ for 20 min before NBS (1.0 equiv) and AIBN (0.1 equiv) were added. The reaction mixture was stirred at 80 °C for 6 h. Upon completion, the reaction mixture was cooled to room temperature and extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. Crude product was purified by column chromatography (5% EtOAc in hexane) to yield desired product.

General Procedure M: Amine Synthesis from Phthalimide Precursor. To a stirred solution of alkyl halide (1.0 equiv) in DMF (70 mL) were added phthalimide (1.7 equiv) and CS₂CO₃ (3.0 equiv). Reaction mixture was stirred at room temperature for 4 h. Upon completion, the reaction mixture was extracted with EtOAc. Organic layer was washed with water and brine and dried over anhydrous Na₂SO₄ and concentrated in vacuo. Crude product was purified by column chromatography (30% EtOAc in hexane) to afford desired product, which was then on-reacted with hydrazine hydrate (3.0 equiv) in *n*-butanol (20 mL) at 80 °C for 1 h. Upon completion, reaction mixture was cooled to room temperature. A voluminous precipitate was formed, which was filtered off. The filtrate was concentrated in vacuo to give crude product, which was purified by column chromatography (neutral Al₂O₃, 10% MeOH in DCM) to yield desired product.

1-Ethyl-*N*-(4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (8) (Exp1). Title compound was prepared according to general procedure G1, starting from **66** and 1-ethyl-1*H*-pyrazole-5-carboxylic acid to give a white solid (30%). ¹H NMR (400 MHz, CDCl₃) δ = 7.85 (d, *J* = 8.5 Hz, 2H), 7.44 (d, *J* = 2.1 Hz, 1H), 7.35 (d, *J* = 8.5 Hz, 2H), 6.87 (s, br, 1H), 6.51 (d, *J* = 2.1 Hz, 2H), 4.65–4.57 (m, 4H), 2.49 (d, *J* = 1.0 Hz, 3H), 1.45 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃) δ = 167.1, 159.9, 154.0, 139.6, 137.8, 134.4, 133.4, 128.3, 127.0, 113.7, 106.4, 46.9, 43.3, 17.3, 16.0 ppm. LC-MS: *m/z* = 326.9 [M + H]⁺.

1-Isopropyl-*N*-(4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (9) (Exp1). Title compound was prepared according to general procedure G1, starting from **66** and 1-isopropyl-1*H*-pyrazole-5-carboxylic acid to give a white solid (42%). ¹H NMR

(400 MHz, CDCl₃) δ = 7.84 (d, *J* = 8.3 Hz, 2H), 7.45 (d, *J* = 1.9 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 6.85 (d, *J* = 0.9 Hz, 1H), 6.71 (s, br, 1H), 6.50 (d, *J* = 2.0 Hz, 1H), 5.57–5.47 (m, 1H), 4.55 (d, *J* = 5.9 Hz, 2H), 2.46 (d, *J* = 0.9 Hz, 3H), 1.47 (d, *J* = 6.6 Hz, 6H) ppm; ¹³C NMR (101 MHz, CDCl₃) δ = 167.5, 160.6, 154.2, 140.0, 138.0, 134.7, 133.4, 128.5, 127.2, 114.0, 106.7, 52.2, 43.5, 23.1, 17.5 ppm. LC-MS: *m/z* = 341.1 [M + H]⁺.

***N*-(4-(4-Ethylthiazol-2-yl)benzyl)-1-methyl-3-(trifluoromethyl)-1*H*-pyrazole-5-carboxamide (10) (Exp2).** Title compound was prepared according to general procedure G2, starting from **70** and 1-methyl-3-(trifluoromethyl)-1*H*-pyrazole-5-carboxylic acid to give a white solid (39%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.29 (br, 1H), 7.89 (d, *J* = 7.8 Hz, 2H), 7.44 (d, *J* = 7.6 Hz, 2H), 7.38 (s, 1H), 7.31 (s, 1H), 4.50 (d, *J* = 5.1 Hz, 2H), 4.15 (s, 3H), 2.80–2.77 (m, 2H), 1.26 (t, *J* = 7.3 Hz, 3H), ppm. LC-MS: *m/z* = 395.0 [M + H]⁺.

3-Cyano-*N*-(4-(4-ethylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (11) (Exp2). Title compound was prepared according to general procedure G3, starting from **70** and **76** to give an off-white solid (29%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.33 (br s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.52 (s, 1H), 7.43 (d, *J* = 7.9 Hz, 2H), 7.32 (s, 1H), 4.50 (d, *J* = 5.6 Hz, 2H), 4.16 (s, 3H), 2.77 (q, *J* = 7.4 Hz, 2H), 1.26 (t, *J* = 7.4, 3H) ppm. LC-MS: *m/z* = 352.1 [M + H]⁺.

3-Ethyl-1-methyl-*N*-(4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (12) (Exp1). Title compound was prepared according to general procedure G1, starting from **66** and 3-ethyl-1-methyl-1*H*-pyrazole-5-carboxylic acid to give a white solid (50%). ¹H NMR (400 MHz, CDCl₃) δ = 7.81 (d, *J* = 8.3 Hz, 2H), 7.27 (d, *J* = 8.3 Hz, 2H), 6.87 (s, br, 1H), 6.84 (d, *J* = 0.9 Hz, 1H), 6.35 (s, 1H), 4.51 (d, *J* = 5.9 Hz, 2H), 4.09 (s, 3H), 2.56 (q, *J* = 7.6 Hz, 2H), 2.45 (d, *J* = 0.9 Hz, 3H), 1.16 (t, *J* = 7.6 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.1, 160.1, 153.9, 152.9, 139.7, 135.4, 133.1, 128.2, 126.8, 113.6, 104.4, 43.0, 38.9, 21.2, 17.2, 13.8 ppm. LC-MS: *m/z* = 340.9 [M + H]⁺.

***N*-(4-(4-Ethylthiazol-2-yl)benzyl)-1-methyl-4-(trifluoromethyl)-1*H*-pyrazole-5-carboxamide (13) (Exp2).** Title compound was prepared according to general procedure G2, starting from **70** and 1-methyl-4-(trifluoromethyl)-1*H*-pyrazole-5-carboxylic acid to give an off-white solid (30%). ¹H NMR (400 MHz, CDCl₃) δ = 7.93 (d, *J* = 8.1 Hz, 2H), 7.67 (s, 1H), 7.38 (d, *J* = 8.0 Hz, 2H), 6.88 (s, 1H), 6.49 (br s, 1H), 4.65 (d, *J* = 5.5 Hz, 2H), 4.10 (s, 3H), 2.86 (q, *J* = 7.4 Hz, 2H), 1.34 (t, *J* = 7.5 Hz, 3H) ppm. LC-MS: *m/z* = 395.2 [M + H]⁺.

4-Cyano-*N*-(4-(4-ethylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (14) (Exp2). To a stirred solution of 4-iodo-1-methyl-1*H*-pyrazole-5-carboxylic acid methyl ester (700 mg, 2.63 mmol) in DMF (10 mL), CuCN (472 mg, 5.26 mmol) was then added. The reaction was stirred at 140 °C for 3 h. Upon completion, the reaction mixture was cooled to room temperature and extracted with EtOAc, washed with saturated NH₄Cl, water, and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. The crude product was purified by column chromatography (30% EtOAc in hexane) to afford methy-4-cyano-1-methyl-1*H*-pyrazole-5-carboxylate as a white solid, which was directly subjected to general procedure F1 to give the corresponding carboxylic acid that was subsequently coupled to **70** according to general procedure G4 to give title compound as an off-white solid (56%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.58 (br, 1H), 8.14 (s, 1H), 7.90 (d, *J* = 7.8 Hz, 2H), 7.49 (d, *J* = 7.8 Hz, 2H), 7.32 (s, 1H), 4.56 (d, *J* = 5.2 Hz, 2H), 3.96 (s, 3H), 2.79–2.75 (m, 2H), 1.27 (t, *J* = 7.3 Hz, 3H) ppm. LC-MS: *m/z* = 352.2 [M + H]⁺.

4-Fluoro-1-methyl-*N*-(4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (15) (Exp1). Title compound was prepared according to general procedure G5, starting from **66** and **78**, to give a white solid (50%). ¹H NMR (400 MHz, CDCl₃) δ = 7.95 (d, *J* = 8.3 Hz, 2H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.37 (d, *J* = 4.5 Hz, 1H), 6.90 (d, *J* = 0.8 Hz, 1H), 6.59 (s, 1H), 4.68 (d, *J* = 5.8 Hz, 2H), 4.20 (d, *J* = 0.7 Hz, 3H), 2.53 (d, *J* = 0.8 Hz, 3H) ppm. LC-MS: *m/z* = 330.9 [M + H]⁺.

4-Chloro-1-methyl-N-(4-(4-methylthiazol-2-yl)benzyl)-1H-pyrazole-5-carboxamide (16) (Exp1). Title compound was prepared according to general procedure G1, starting from **66** and 4-chloro-1-methyl-1H-pyrazole-5-carboxylic acid, to give a white solid (22%). ¹H NMR (400 MHz, CDCl₃) δ = 7.92 (d, *J* = 8.3 Hz, 2H), 7.45–7.38 (m, 3H), 7.04 (s, br, 1H), 6.87 (d, *J* = 0.9 Hz, 1H), 4.67 (d, *J* = 5.8 Hz, 2H), 4.19 (s, 3H), 2.50 (d, *J* = 0.9 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.1, 158.4, 154.0, 139.2, 136.8, 133.4, 130.9, 128.2, 127.0, 113.7, 109.7, 43.3, 41.32, 17.4 ppm. LC-MS: *m/z* = 346.8 [M + H]⁺.

4-Chloro-N-(4-(4-ethylthiazol-2-yl)benzyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (17) (Exp2). Title compound was prepared according to general procedure G2, starting from **70** and 4-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid, to give a white solid (14%). ¹H NMR (400 MHz, CDCl₃) δ = 7.93 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 7.9 Hz, 2H), 6.99 (br, 1H), 6.88 (s, 1H), 4.68 (d, *J* = 5.4 Hz, 2H), 4.23 (s, 3H), 2.86 (q, *J* = 7.4 Hz, 2H), 1.34 (t, *J* = 7.4 Hz, 3H) ppm. LC-MS: *m/z* = 429.0 [M + H]⁺.

4-Chloro-3-methoxy-1-methyl-N-(4-(4-methylthiazol-2-yl)benzyl)-1H-pyrazole-5-carboxamide (18) (Exp1). To a solution of methyl 3-methoxy-1-methyl-1H-pyrazole-5-carboxylate (0.5 g, 2.94 mmol) in toluene (10 mL) was added SO₂Cl₂ (0.48 mL, 5.88 mmol) dropwise. The mixture was heated at 100 °C for 2 h, then cooled to room temperature. Water (20 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 10 mL). Combined organic layer was washed with brine, dried over MgSO₄, and concentrated in vacuo to afford methyl 4-chloro-3-methoxy-1-methyl-1H-pyrazole-5-carboxylate, which was directly subjected to general procedure F3 to give the corresponding carboxylic acid, which was subsequently coupled to **66** according to general procedure G3 to give title compound (20%). ¹H NMR (400 MHz, CDCl₃) δ = 7.92 (d, *J* = 8.3 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.02 (s, br, 1H), 6.87 (s, 1H), 4.65 (d, *J* = 5.7 Hz, 2H), 4.06 (s, 3H), 3.96 (s, 3H), 2.50 (s, 3H) ppm. LC-MS: *m/z* = 376.8 [M + H]⁺.

2-Methyl-N-(4-(4-methylthiazol-2-yl)benzyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide (19) (Exp1). Title compound was prepared according to general procedure G1, starting from **66** and 2-methyl-2,4,5,6-tetrahydrocyclopenta[c]-pyrazole-3-carboxylic acid to give a white solid (20%). ¹H NMR (400 MHz, CDCl₃) δ = 7.92 (d, *J* = 8.2 Hz, 2H), 7.37 (d, *J* = 8.1 Hz, 2H), 6.88 (s, 1H), 6.04 (s, br, 1H), 4.63 (d, *J* = 5.9 Hz, 2H), 4.17 (s, 3H), 2.77–2.70 (m, 4H), 2.51 (s, 3H), 2.49–2.42 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.1, 160.3, 159.2, 154.0, 139.8, 133.4, 129.2, 128.1, 127.0, 125.4, 113.7, 43.2, 39.8, 30.0, 24.7, 24.6, 17.4 ppm. LC-MS: *m/z* = 352.8 [M + H]⁺.

1-Methyl-N-(4-(thiazol-2-yl)benzyl)-1H-pyrazole-5-carboxamide (20) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromothiazole to give a brown solid (63%). ¹H NMR (400 MHz, CDCl₃) δ = 7.91 (d, *J* = 8.3 Hz, 2H), 7.84 (d, *J* = 3.2 Hz, 1H), 7.42 (d, *J* = 2.0 Hz, 1H), 7.37 (d, *J* = 8.2 Hz, 2H), 7.33 (d, *J* = 3.3 Hz, 1H), 6.63 (s, br, 1H), 6.54 (d, *J* = 2.0 Hz, 1H), 4.59 (d, *J* = 5.9 Hz, 2H), 4.19 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.9, 160.0, 143.8, 139.8, 137.7, 135.0, 133.2, 128.4, 127.1, 119.11, 106.4, 43.2, 39.5 ppm. LC-MS: *m/z* = 299.1 [M + H]⁺.

N-(4-(4,5-Dimethylthiazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (21) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromo-4,5-dimethylthiazole, to give a brown solid (57%). ¹H NMR (400 MHz, CDCl₃) δ = 7.66 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 2.1 Hz, 1H), 7.17 (d, *J* = 8.3 Hz, 2H), 6.97 (s, br, 1H), 6.51 (d, *J* = 2.1 Hz, 1H), 4.43 (d, *J* = 5.9 Hz, 2H), 4.09 (s, 3H), 2.27 (d, *J* = 11.6 Hz, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 163.2, 160.3, 149.6, 139.5, 137.9, 135.4, 133.5, 128.4, 127.1, 126.7, 106.9, 43.4, 39.7, 15.1, 11.8 ppm. LC-MS: *m/z* = 326.9 [M + H]⁺.

N-(4-(Benzo[d]thiazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (22) (Exp1). Title compound was prepared according to general procedure A1 starting from **79** and 2-chlorobenzo[d]-thiazole, to give a brown solid (50%). ¹H NMR (400 MHz, CDCl₃) δ

= 8.04 (t, *J* = 6.9 Hz, 3H), 7.89 (d, *J* = 8.0 Hz, 1H), 7.49 (t, *J* = 7.7 Hz, 1H), 7.46–7.34 (m, 4H), 6.61 (s, br, 1H), 6.56 (s, 1H), 4.62 (d, *J* = 5.9 Hz, 2H), 4.21 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.5, 160.1, 154.2, 140.9, 137.7, 135.1, 135.0, 133.2, 128.4, 128.1, 126.5, 125.4, 123.3, 121.7, 106.4, 43.3, 39.5 ppm. LC-MS: *m/z* = 348.9 [M + H]⁺.

1-Methyl-N-(4-(2-methylthiazol-4-yl)benzyl)-1H-pyrazole-5-carboxamide (23) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 4-bromo-2-methylthiazole to give a brown solid (56%). ¹H NMR (400 MHz, CDCl₃) δ = 8.60 (s, 1H), 7.61 (d, *J* = 8.3 Hz, 2H), 7.39 (d, *J* = 2.1 Hz, 1H), 7.36 (d, *J* = 8.3 Hz, 2H), 6.76 (s, br, 1H), 6.53 (d, *J* = 2.1 Hz, 1H), 4.58 (d, *J* = 5.8 Hz, 2H), 4.18 (s, 3H), 2.57 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 160.0, 151.3, 149.4, 137.6, 137.2, 135.2, 134.4, 129.0, 128.3, 127.9, 106.5, 43.3, 39.4, 12.6 ppm. LC-MS: *m/z* = 312.9 [M + H]⁺.

1-Methyl-N-(4-(4-methylthiazol-2-yl)methyl)benzyl)-1H-pyrazole-5-carboxamide (24) (Exp2). Intermediate **82** was subjected to general procedure B2 to give the corresponding benzylamine, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4 to afford title compound as a gummy liquid (31%). ¹H NMR (400 MHz, CDCl₃) δ = 7.42 (d, *J* = 1.8 Hz, 1H), 7.33–7.28 (m, 4H), 6.73 (s, 1H), 6.46 (d, *J* = 1.8 Hz, 1H), 6.23 (br s, 1H), 4.56 (d, *J* = 5.6 Hz, 2H), 4.27 (s, 2H), 4.19 (s, 3H), 2.41 (s, 3H) ppm. LC-MS: *m/z* = 327.1 [M + H]⁺.

N-(4-(4-Chlorothiazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (25) (Exp1). Title compound was prepared according to general procedure G1, starting from **79** and 2-bromo-4-chlorothiazole, to give a brown solid (43%). ¹H NMR (400 MHz, CDCl₃) δ = 7.86 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 2.1 Hz, 1H), 7.36 (d, *J* = 8.3 Hz, 2H), 7.07 (s, 1H), 6.61 (s, br, 1H), 6.54 (d, *J* = 2.1 Hz, 1H), 4.59 (d, *J* = 6.0 Hz, 2H), 4.18 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 167.2, 159.7, 140.3, 139.8, 137.4, 134.6, 131.8, 128.1, 126.4, 112.8, 106.2, 42.8, 39.1 ppm. LC-MS: *m/z* = 332.9 [M + H]⁺.

1-Methyl-N-(4-(4-(trifluoromethyl)thiazol-2-yl)benzyl)-1H-pyrazole-5-carboxamide (26) (Exp2). Intermediate **84** was subjected to general procedure B2 to give the corresponding benzylamine, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4, to afford title compound as a white solid (28%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.10 (br, 1H), 8.54 (s, 1H), 7.97 (d, *J* = 8.1 Hz, 2H), 7.48–7.46 (m, 3H), 6.92 (s, 1H), 4.50 (d, *J* = 5.9 Hz, 2H), 4.06 (s, 3H) ppm. LC-MS: *m/z* = 367.2 [M + H]⁺.

1-Methyl-N-(4-(4-(2,2,2-trifluoroethyl)thiazol-2-yl)benzyl)-1H-pyrazole-5-carboxamide (27) (Exp2). General procedure D3 was followed, starting from 1-bromo-4,4,4-trifluorobutan-2-one and 4-bromo-thiobenzamide to give 2-(4-bromophenyl)-4-(2,2,2-trifluoroethyl)-1,3-thiazole, which was subjected to cyanation, then reduction according to general procedure C and general procedure B2 respectively to give the corresponding benzylamine, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4 to afford title compound as a white solid (22%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.08 (t, *J* = 5.3 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.70 (s, 1H), 7.47–7.43 (m, 3H), 6.91 (s, 1H), 4.49 (d, *J* = 5.3 Hz, 2H), 4.06 (s, 3H), 3.90–3.84 (m, 2H) ppm. LC-MS: *m/z* = 381.1 [M + H]⁺.

N-(4-(4-(1,1-Difluoroethyl)thiazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (28) (Exp2). Title compound was prepared according to general procedure G4, starting from **90** and 1-methyl-1H-pyrazole-5-carboxylic acid, to give a white solid (16%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.20–8.90 (m, 1 H), 8.08 (s, 1H), 7.94 (d, *J* = 8.1 Hz, 2H), 7.47–7.45 (m, 3H), 6.92 (d, *J* = 1.7 Hz, 1H), 4.50 (d, *J* = 5.8 Hz, 2H), 4.06 (s, 3H), 2.06 (t, *J* = 18.8 Hz, 3H) ppm; LC-MS: *m/z* = 363.2 [M + H]⁺.

N-(4-(1,4-Dimethyl-1H-imidazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (29) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromo-1,4-dimethyl-1H-imidazole, to give a brown solid (37%). ¹H

NMR (400 MHz, CDCl_3) δ = 8.49 (s, 1H), 7.40–7.30 (m, 3H), 7.18 (d, J = 7.9 Hz, 2H), 6.72 (s, br, 1H), 6.65 (s, 1H), 4.47 (d, J = 5.4 Hz, 2H), 4.15 (s, 3H), 3.59 (s, 3H), 2.15 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 160.3, 146.8, 139.1, 137.5, 137.0, 135.3, 128.9, 128.7, 127.5, 119.1, 107.1, 42.6, 39.4, 34.2, 13.2 ppm. LC-MS: m/z = 310.2 $[\text{M} + \text{H}]^+$.

1-Methyl-N-(4-(1-methyl-1H-pyrazol-3-yl)benzyl)-1H-pyrazole-5-carboxamide (30) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 3-bromo-1-methyl-1H-pyrazole, to give a white solid (31%). ^1H NMR (400 MHz, CDCl_3) δ = 7.73 (d, J = 8.2 Hz, 2H), 7.37 (dd, J = 14.0, 2.1 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 6.64 (s, br, 1H), 6.51 (dd, J = 3.2, 2.3 Hz, 2H), 4.54 (d, J = 5.8 Hz, 2H), 4.17 (s, 3H), 3.91 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 159.9, 151.1, 137.6, 136.9, 135.2, 133.1, 131.5, 128.2, 126.0, 106.4, 103.0, 43.4, 39.4, 39.1 ppm. LC-MS: m/z = 296.0 $[\text{M} + \text{H}]^+$.

N-(4-(1-Ethyl-1H-pyrazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (31) (Exp2). Intermediate **94** was subjected to general procedure B2 to give the corresponding benzylamine, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4, to afford title compound as a brown gummy liquid (23%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.01 (br, 1H), 7.74–7.73 (m, 3H), 7.46 (s, 1H), 7.31 (d, J = 8.0 Hz, 2H), 6.90 (s, 1H), 6.64 (s, 1H), 4.44 (d, J = 5.9 Hz, 2H), 4.15 (q, J = 7.3 Hz, 2H), 4.06 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H) ppm. LC-MS: m/z = 310.3 $[\text{M} + \text{H}]^+$.

N-(4-(4-Ethyl-2H-1,2,3-triazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (32) (Exp2). Intermediate **95** was subjected to general procedure B2 to give the corresponding benzylamine, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G2 to afford title compound as a white solid (66%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.07 (t, J = 5.5 Hz, 1H), 7.94–7.91 (m, 3H), 7.47–7.45 (m, 3H), 6.91 (s, 1H), 4.49 (d, J = 5.5 Hz, 2H), 4.07 (s, 3H), 2.75 (q, J = 7.6 Hz, 2H), 1.27 (t, J = 7.4 Hz, 3H) ppm. LC-MS: m/z = 311.2 $[\text{M} + \text{H}]^+$.

N-(4-(3-Ethyl-1H-1,2,4-triazol-5-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (33) (Exp2). Title compound was prepared according to general procedure G2, starting from **98** and 1-methyl-1H-pyrazole-5-carboxylic acid to give a white solid (40 mg, 33%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 100 °C) δ = 13.33 (br s, 1H), 8.71 (t, J = 5.2 Hz, 1H), 7.94 (d, J = 7.0 Hz, 2H), 7.41 (d, J = 8.0 Hz, 3H), 6.86 (s, 1H), 4.49 (d, J = 5.2 Hz, 2H), 4.06 (s, 3H), 2.75–2.66 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H) ppm. LC-MS: m/z = 311.2 $[\text{M} + \text{H}]^+$.

N-(4-(1-Ethyl-1H-1,2,4-triazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (34) (Exp2). To a stirred solution of **100** (0.25 g, 0.78 mmol) in pyridine (10.0 mL), ethyl-hydrazine HCl (0.42 g, 4.37 mmol) was added. Reaction mixture was stirred at room temperature for 16 h then concentrated in vacuo. Residue was washed with diethyl ether (2 $\times$ 10 mL) to afford N-(4-((2-ethylhydrazinyl)(imino)methyl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide, which was dissolved in formic acid (4.0 mL) and stirred at 80 °C for 16 h. Reaction mixture was cooled to room temperature and quenched with saturated NaHCO_3 solution. The aqueous layer was extracted with EtOAc (3 $\times$ 10 mL). The combined organic layer was washed with water and brine and dried over anhydrous Na_2SO_4 then concentrated in vacuo. Crude product was purified by column chromatography (2% MeOH in DCM) to afford title compound (26%) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.01 (t, J = 5.6 Hz, 1H), 8.51 (s, 1H), 7.92 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 1.6 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 6.89 (d, J = 1.7 Hz, 1H), 4.45 (d, J = 6.0 Hz, 2H), 4.20 (q, J = 7.3 Hz, 2H), 4.03 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H) ppm. LC-MS: m/z = 311.2 $[\text{M} + \text{H}]^+$.

N-(4-(4-Ethyl-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (35) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromo-4-ethyl-oxazole, to give a brown solid (55%). ^1H NMR (400 MHz, CDCl_3) δ = 8.00 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 2.1 Hz, 1H), 7.40 (d, J = 8.7 Hz, 3H), 6.52 (d, J = 2.1 Hz, 1H), 6.38 (s, br, 1H), 4.63 (d, J = 5.9 Hz, 2H), 4.21 (s, 3H), 2.62 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.5 Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 160.9, 159.8, 144.2,

139.7, 137.6, 134.9, 133.5, 128.0, 127.3, 126.7, 106.2, 43.2, 39.3, 19.9, 12.6 ppm. LC-MS: m/z = 310.9 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (36) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromo-5-ethyl-oxazole, to give a brown solid (94%). ^1H NMR (400 MHz, CDCl_3) δ = 7.95 (d, J = 7.1 Hz, 2H), 7.42 (s, 1H), 7.37 (d, J = 7.2 Hz, 2H), 6.81 (s, 1H), 6.56 (s, br, 1H), 6.54 (s, 1H), 4.60 (d, J = 3.9 Hz, 2H), 4.20 (s, 3H), 2.84–2.67 (q, J = 7.6 Hz, 2H), 1.30 (t, J = 7.5 Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 160.2, 159.9, 154.5, 139.5, 137.6, 134.9, 128.0, 127.3, 126.4, 122.9, 106.3, 43.2, 39.3, 19.1, 11.8 ppm. LC-MS: m/z = 310.9 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-1,2,4-oxadiazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (37) (Exp2). Title compound was prepared according to general procedure J1, starting from **101** and propionic acid, to give a white solid (38%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.09 (br, 1H), 7.97 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 8.0 Hz, 3H), 6.92 (s, 1H), 4.51 (d, J = 5.5 Hz, 2H), 4.06 (s, 3H), 3.01 (q, J = 7.4 Hz, 2H), 1.33 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 312.2 $[\text{M} + \text{H}]^+$.

N-(4-(3-Ethyl-1,2,4-oxadiazol-5-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (38) (Exp2). General procedure J1 was followed, starting from **102** and **103**, to give *tert*-butyl 4-(3-ethyl-1,2,4-oxadiazol-5-yl)benzyl)carbamate, which was then subjected to general procedure K to give the corresponding HCl salt, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4 to afford the title compound as an off-white solid (63%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.13 (t, J = 5.7 Hz, 1H), 8.07 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.48 (s, 1H), 6.93 (s, 1H), 4.54 (d, J = 5.8 Hz, 2H), 4.06 (s, 3H), 2.79 (q, J = 7.5, 2H), 1.28 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 312.2 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-1,3,4-oxadiazol-2-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (39) (Exp1). General procedure G1 was followed, starting from methyl 4-(aminomethyl)benzoate HCl and 1-methyl-1H-pyrazole-5-carboxylic acid to give methyl 4-((1-methyl-1H-pyrazole-5-carboxamido)methyl)benzoate, which was then directly reacted with hydrazide monohydrate (9.15 mmol) in EtOH at room temperature overnight. Upon completion, EtOH was removed in vacuo and iced water was added to residue, and the resulting white precipitate was filtered, dried, and redissolved in EtOH. Propionaldehyde (0.3 mmol) was then added, and the reaction was refluxed for 3 h then cooled to room temperature. EtOH was removed in vacuo, and the residue was dissolved in minimal amount of DMSO. K_2CO_3 (1.1 mmol) and I_2 (0.4 mmol) were then added, and the reaction was stirred at 100 °C for 4 h. Upon completion (monitored by TLC), EtOAc was added to the reaction and organic was washed with $\text{Na}_2\text{S}_2\text{O}_3$, then water, then dried (MgSO_4). Solvent was removed in vacuo to give crude product, which was purified by column chromatography in 0–5% MeOH/DCM to give the title compound as a white solid (10%). ^1H NMR (400 MHz, CDCl_3) δ = 7.93 (d, J = 8.4 Hz, 2H), 7.41–7.38 (m, 3H), 6.91 (s, br, 1H), 6.61 (d, J = 2.1 Hz, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.18 (s, 3H), 2.93 (q, J = 7.6 Hz, 2H), 1.41 (t, J = 7.6 Hz, 3H) ppm. LCMS: m/z = 311.9 $[\text{M} + \text{H}]^+$.

1-Methyl-N-(4-(pyridin-2-yl)benzyl)-1H-pyrazole-5-carboxamide (40) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromopyridine, to give a pink gummy liquid (10%). ^1H NMR (400 MHz, CDCl_3) δ = 8.91 (d, J = 5.4 Hz, 1H), 8.44 (t, J = 7.7 Hz, 1H), 8.07 (d, J = 7.7 Hz, 1H), 7.82 (d, J = 8.3 Hz, 3H), 7.54 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 5.8 Hz, 1H), 6.69 s, br, 1H), 4.64 (d, J = 5.9 Hz, 2H), 4.19 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 160.0, 153.6, 145.6, 143.1, 142.7, 137.4, 135.4, 129.9, 129.2, 128.6, 125.4, 124.8, 107.1, 43.1, 39.1 ppm. LCMS: m/z = 293.0 $[\text{M} + \text{H}]^+$.

1-Methyl-N-(4-(pyridazin-3-yl)benzyl)-1H-pyrazole-5-carboxamide (41) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 3-bromopyridazine, to give a brown solid (25%). ^1H NMR (400 MHz, CDCl_3) δ = 9.09 (dd, J = 4.9, 1.5 Hz, 1H), 7.94 (d, J = 8.3 Hz, 2H), 7.81 (dd, J = 8.6, 1.5 Hz, 1H), 7.51 (dd, J = 8.6, 4.9 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H),

7.38 (d, $J = 2.1$ Hz, 1H), 7.29 (s, br, 1H), 6.65 (d, $J = 2.1$ Hz, 1H), 4.60 (d, $J = 6.0$ Hz, 2H), 4.17 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 160.2, 159.2, 150.0, 140.3, 137.6, 135.5, 135.1, 128.3, 127.5, 127.0, 124.0, 106.7, 43.1, 39.4. LCMS $m/z = 293.9$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(4-(pyrazin-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (42) (Exp1). Title compound was prepared according to general procedure A1, starting from **79** and 2-bromopyrazine, to give a white (10%). ^1H NMR (400 MHz, CDCl_3) δ 8.99 (d, $J = 1.5$ Hz, 1H), 8.62 (dd, $J = 2.5, 1.6$ Hz, 1H), 8.50 (d, $J = 2.5$ Hz, 1H), 7.99 (d, $J = 8.4$ Hz, 2H), 7.46 (d, $J = 8.4$ Hz, 2H), 7.43 (d, $J = 2.1$ Hz, 1H), 6.53 (d, $J = 2.1$ Hz, 2H), 4.65 (d, $J = 5.9$ Hz, 2H), 4.21 (d, $J = 3.7$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 160.0, 152.4, 144.3, 143.1, 142.2, 139.8, 137.7, 135.9, 135.0, 128.5, 127.5, 106.4, 43.3, 39.5 ppm. LCMS $m/z = 293.9$ [$\text{M} + \text{H}$] $^+$.

***N*-(2-Fluoro-4-(4-methylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (43) (Exp2).** Title compound was prepared according to general procedure G4, starting from **104** and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give a white solid (46%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.05 (t, $J = 6.0$ Hz, 1H), 7.73–7.67 (m, 2H), 7.48–7.47 (m, 2H), 7.37 (s, 1H), 6.93 (d, $J = 1.9$ Hz, 1H), 4.50 (d, $J = 5.8$ Hz, 2H), 4.05 (s, 3H), 2.42 (s, 3H) ppm. LC-MS: $m/z = 331.2$ [$\text{M} + \text{H}$] $^+$.

***N*-(2-Methoxy-4-(4-methylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (44) (Exp1).** General procedure G1 was followed, starting from (4-bromo-2-methoxyphenyl)-methanamine and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give *N*-(4-bromo-2-methoxybenzyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a white solid (42%). ^1H NMR (400 MHz, CDCl_3) δ 7.53 (s, 1H), 7.42–7.38 (m, 2H), 7.33 (d, $J = 7.7$ Hz, 1H), 6.87 (s, 1H), 6.63 (s, br, 1H), 6.48 (d, $J = 1.8$ Hz, 1H), 4.58 (d, $J = 5.9$ Hz, 2H), 4.16 (s, 3H), 3.96 (s, 3H), 2.50 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 167.2, 159.8, 158.0, 153.9, 137.6, 135.4, 134.8, 130.2, 127.6, 119.3, 113.8, 108.2, 106.2, 55.8, 39.4, 39.3, 17.3 ppm. LC-MS: $m/z = 342.9$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(2-methyl-4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (45) (Exp1). General procedure G1 was followed, starting from (4-bromo-2-methylphenyl)methanamine HCl and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give *N*-(4-bromo-2-methylbenzyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a white solid (39%). ^1H NMR (400 MHz, CDCl_3) δ 7.73 (s, 1H), 7.66 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.40 (d, $J = 2.1$ Hz, 1H), 7.25 (d, $J = 8.0$ Hz, 1H), 6.86 (d, $J = 0.9$ Hz, 1H), 6.54 (d, $J = 2.1$ Hz, 1H), 6.52 (s, br, 1H), 4.56 (d, $J = 5.6$ Hz, 2H), 4.18 (s, 3H), 2.48 (d, $J = 0.9$ Hz, 3H), 2.36 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 167.3, 159.8, 153.9, 137.7, 137.2, 137.2, 135.0, 133.3, 128.9, 128.4, 124.4, 113.6, 106.4, 41.4, 39.4, 19.1, 17.3 ppm. LC-MS: $m/z = 326.9$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(5-(4-methylthiazol-2-yl)pyridin-2-yl)methyl)-1*H*-pyrazole-5-carboxamide (46) (Exp2). General procedure B3 was followed, starting from **105** to give (5-(4-methylthiazol-2-yl)pyridin-2-yl)methanamine HCl, which was subsequently coupled to 1-methyl-1*H*-pyrazole-5-carboxylic acid according to general procedure G4 to give the title compound as an off-white solid (15%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.16 (t, $J = 5.8$ Hz, 1H), 9.03 (s, 1H), 8.26–8.24 (m, 1H), 7.49–7.41 (m, 3H), 6.96 (d, $J = 1.6$ Hz, 1H), 4.58 (d, $J = 5.8$ Hz, 2H), 4.06 (s, 3H), 2.44 (s, 3H) ppm. LC-MS: $m/z = 314.3$ [$\text{M} + \text{H}$] $^+$.

***N*-(3-Fluoro-4-(4-methylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (47) (Exp2).** Title compound was prepared according to general procedure G4, starting from **106** and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give a white solid (15% yields). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.09 (t, $J = 5.9$ Hz, 1H), 8.17 (t, $J = 7.8$ Hz, 1H), 7.46 (d, $J = 9.8$ Hz, 2H), 7.34–7.28 (m, 2H), 6.92 (s, 1H), 4.50 (d, $J = 5.9$ Hz, 2H), 4.06 (s, 3H), 2.45 (s, 3H) ppm. LC-MS: $m/z = 331.0$ [$\text{M} + \text{H}$] $^+$.

***N*-(3-Methoxy-4-(4-methylthiazol-2-yl)benzyl)-1-methyl-1*H*-pyrazole-5-carboxamide (48) (Exp1).** General procedure G1 was followed, starting from (4-bromo-3-methoxyphenyl)-

methanamine and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give *N*-(4-bromo-3-methoxybenzyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a brown solid (33% yields). ^1H NMR (400 MHz, CDCl_3) δ 8.28 (d, $J = 8.0$ Hz, 1H), 7.44 (d, $J = 2.1$ Hz, 1H), 6.97 (dd, $J = 8.0, 1.5$ Hz, 1H), 6.95–6.93 (m, 2H), 6.56 (s, br, 1H), 6.55 (d, $J = 2.1$ Hz, 1H), 4.58 (d, $J = 5.9$ Hz, 2H), 4.21 (s, 3H), 3.98 (s, 3H), 2.50 (d, $J = 0.9$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 161.4, 160.0, 156.6, 151.9, 140.3, 137.7, 135.1, 128.8, 122.0, 120.3, 114.9, 110.9, 106.4, 55.7, 43.5, 39.5, 17.3. LC-MS: $m/z = 342.8$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(3-methyl-4-(4-methylthiazol-2-yl)benzyl)-1*H*-pyrazole-5-carboxamide (49) (Exp1). General procedure G1 was followed, starting from (4-bromo-3-methylphenyl)methanamine HCl and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give *N*-(4-bromo-3-methylbenzyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a brown solid (41% yields). ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, $J = 7.9$ Hz, 1H), 7.40 (d, $J = 2.1$ Hz, 1H), 7.18 (s, 1H), 7.15 (d, $J = 7.9$ Hz, 1H), 6.93 (d, $J = 0.9$ Hz, 1H), 6.72 (s, br, 1H), 6.53 (d, $J = 2.1$ Hz, 1H), 4.53 (d, $J = 5.9$ Hz, 2H), 4.17 (s, 3H), 2.53 (s, 3H), 2.49 (d, $J = 0.9$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 166.5, 160.0, 153.1, 138.8, 137.6, 137.0, 135.1, 132.7, 130.6, 130.4, 125.3, 114.3, 106.5, 43.1, 39.4, 21.4, 17.3 ppm. LC-MS: $m/z = 326.9$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(6-(4-methylthiazol-2-yl)pyridin-3-yl)methyl)-1*H*-pyrazole-5-carboxamide (50) (Exp2). General procedure B3 was followed, starting from **107**, to give the corresponding HCl salt, which was subsequently coupled to 1-methyl-1*H*-pyrazole-5-carboxylic acid according to general procedure G4 to give the title compound as an off-white solid (19%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.10 (t, $J = 5.8$ Hz, 1H), 8.57 (d, $J = 1.2$ Hz, 1H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.85 (dd, $J = 8.2, 1.9$ Hz, 1H), 7.47 (d, $J = 2.0$ Hz, 1H), 7.40 (s, 1H), 6.90 (d, $J = 2.0$ Hz, 1H), 4.51 (d, $J = 5.9$ Hz, 2H), 4.06 (s, 3H), 2.44 (s, 3H) ppm. LC-MS: $m/z = 314.3$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(1-(4-(4-methylthiazol-2-yl)phenyl)ethyl)-1*H*-pyrazole-5-carboxamide (51) (Exp1). General procedure G1 was followed, starting from 1-(4-bromophenyl)ethan-1-amine HCl and 1-methyl-1*H*-pyrazole-5-carboxylic acid to give *N*-(1-(4-bromophenyl)-ethyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a brown gummy liquid (35% yields). ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 8.2$ Hz, 2H), 7.45–7.43 (m, 1H), 7.41 (d, $J = 8.2$ Hz, 2H), 6.87 (s, 1H), 6.51 (d, $J = 1.5$ Hz, 1H), 6.23 (s, br, 1H), 5.31–5.22 (m, 1H), 4.16 (s, 3H), 2.50 (s, 3H), 1.60 (d, $J = 6.9$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 167.1, 159.3, 154.0, 148.5, 144.5, 137.7, 133.3, 127.0, 126.8, 113.6, 106.3, 48.9, 39.4, 21.8, 17.4 ppm. LC-MS: $m/z = 326.9$ [$\text{M} + \text{H}$] $^+$.

***N*-(Cyano(4-(4-methylthiazol-2-yl)phenyl)methyl)-1-methyl-1*H*-pyrazole-5-carboxamide (52) (Exp1).** General procedure G1 was followed, starting from 2-amino-2-(4-bromophenyl)ACN and 1-methyl-1*H*-pyrazole-5-carboxylic acid, to give *N*-((4-bromophenyl)-(cyano)methyl)-1-methyl-1*H*-pyrazole-5-carboxamide, which was then subjected to general procedure A6 to afford the title compound as a yellow solid (43% yields). ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, $J = 8.4$ Hz, 2H), 7.69 (d, $J = 8.4$ Hz, 1H), 7.45 (d, $J = 2.1$ Hz, 1H), 7.42 (d, $J = 8.3$ Hz, 2H), 6.95 (d, $J = 0.8$ Hz, 1H), 6.77 (d, $J = 2.1$ Hz, 1H), 6.30 (d, $J = 8.5$ Hz, 1H), 4.23 (s, 3H), 2.50 (d, $J = 0.6$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 166.3, 158.9, 154.2, 137.8, 134.6, 134.0, 127.6, 127.1, 116.7, 114.6, 107.5, 43.5, 39.7, 17.0 ppm. LC-MS: $m/z = 337.9$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl)-1*H*-pyrazole-5-carboxamide (53) (Exp2). Title compound was prepared according to general procedure J1, starting from **101** and acetic acid to give a white solid (21%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.09 (t, $J = 5.8$ Hz, 2H), 7.97 (d, $J = 8.0$ Hz, 2H), 7.50–7.48 (m, 2H), 6.92 (d, $J = 1.6$ Hz, 1H), 4.51 (d, $J = 5.8$ Hz, 2H), 4.06 (s, 3H), 2.65 (s, 3H) ppm. LC-MS: $m/z = 298.3$ [$\text{M} + \text{H}$] $^+$.

1-Methyl-*N*-(4-(5-propyl-1,2,4-oxadiazol-3-yl)benzyl)-1*H*-pyrazole-5-carboxamide (54) (Exp1). Title compound was

prepared according to general procedure J2, starting from **101** and butyric acid, to give a brown solid (34%). ^1H NMR (400 MHz, CDCl_3) δ = 8.00 (d, J = 8.4 Hz, 2H), 7.40–7.35 (m, 3H), 6.80 (s, br, 1H), 6.55 (d, J = 2.1 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 4.15 (s, 3H), 2.89 (t, J = 7.5 Hz, 2H), 1.93–1.82 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 180.0, 167.9, 160.0, 141.0, 137.6, 135.0, 128.1, 127.8, 126.4, 106.5, 43.2, 39.4, 28.5, 20.2, 13.7 ppm. LC-MS: m/z = 325.9 $[\text{M} + \text{H}]^+$.

N-(4-(5-Isopropyl-1,2,4-oxadiazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (55) (Exp1). Title compound was prepared according to general procedure J2, starting from **101** and isobutyric acid, to give a brown solid (35%). ^1H NMR (400 MHz, CDCl_3) δ = 8.02 (d, J = 8.4 Hz, 2H), 7.39 (dd, J = 6.5, 5.3 Hz, 3H), 6.67 (s, br, 1H), 6.54 (d, J = 2.1 Hz, 1H), 4.60 (d, J = 6.0 Hz, 2H), 4.17 (s, 3H), 3.32–3.21 (m, 1H), 1.44 (d, J = 7.0 Hz, 6H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 184.1, 167.9, 160.0, 140.9, 137.7, 135.0, 128.1, 127.9, 126.5, 106.5, 43.2, 39.4, 27.6, 20.2 ppm. LC-MS: m/z = 325.9 $[\text{M} + \text{H}]^+$.

N-(4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (56) (Exp2). Title compound was prepared according to general procedure J1, starting from **101** and cyclopropanecarboxylic acid, to give a white solid (28%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.09 (t, J = 5.9 Hz, 1H), 7.93 (d, J = 8.2 Hz, 2H), 7.48–7.46 (m, 3H), 6.92 (d, J = 1.9 Hz, 1H), 4.51 (d, J = 6.0 Hz, 2H), 4.06 (s, 3H), 2.43–2.36 (m, 1H), 1.30–1.25 (m, 2H), 1.20–1.16 (m, 2H) ppm; LC-MS: m/z = 324.3 $[\text{M} + \text{H}]^+$.

1-Methyl-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)-1H-pyrazole-5-carboxamide (57) (Exp2). Title compound was prepared according to general procedure J1, starting from **101** and TFA, to give a brown solid (15%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.12 (t, J = 5.8 Hz, 1H), 8.05 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 1.9 Hz, 1H), 6.93 (d, J = 2.0 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.06 (s, 3H) ppm. LC-MS: m/z = 352.1 $[\text{M} + \text{H}]^+$.

N-(4-(5-(1,1-Difluoroethyl)-1,2,4-oxadiazol-3-yl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (58) (Exp2). Title compound was prepared according to general procedure J1, starting from **101** and 2,2-difluoropropanoic acid, to give a white solid (27%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.12 (t, J = 5.9 Hz, 1H), 8.03 (d, J = 8.16 Hz, 2H), 7.53 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 1.9 Hz, 1H), 6.93 (d, J = 2.0 Hz, 1H), 4.53 (d, J = 6.0 Hz, 2H), 4.06 (s, 3H), 2.24 (t, J = 19.6 Hz, 3H) ppm. LC-MS: m/z = 348.1 $[\text{M} + \text{H}]^+$.

Synthesis of 1-Methyl-N-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]-1H-pyrazole-5-carboxamide (59) (Exp2). General procedure J1 was followed, starting from **102** and *N*-hydroxyacetimidamide, to give *tert*-butyl (4-(3-methyl-1,2,4-oxadiazol-5-yl)benzyl)carbamate, which was then subjected to general procedure K to give the corresponding HCl salt, which was subsequently coupled to 1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G4 to afford the title compound as a white solid (22%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.12 (t, J = 5.8 Hz, 1H), 8.06 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 1.8 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 4.54 (d, J = 5.8 Hz, 2H), 4.06 (s, 3H), 2.41 (s, 3H) ppm. LC-MS: m/z = 298 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-1,2,4-oxadiazol-3-yl)benzyl)-4-fluoro-1-methyl-1H-pyrazole-5-carboxamide (60) (Exp2). Title compound was prepared according to general procedure J1, starting from **109** and propionic acid, to give a white solid (23%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) (MMV1558288): δ = 8.80 (br, 1H), 7.97 (d, J = 7.80 Hz, 2H), 7.60 (d, J = 3.9 Hz, 1H), 7.50 (d, J = 7.7 Hz, 2H), 4.53 (d, J = 5.4 Hz, 2H), 3.95 (s, 3H), 3.01 (q, J = 7.5 Hz, 2H), 1.34 (t, J = 7.3 Hz, 3H) ppm. LC-MS: m/z = 330.1 $[\text{M} + \text{H}]^+$.

N-(4-(3-Ethyl-1,2,4-oxadiazol-5-yl)benzyl)-4-fluoro-1-methyl-1H-pyrazole-5-carboxamide (61) (Exp2). General procedure J1 was followed, starting from **102** and **103**, to give *tert*-butyl (4-(3-ethyl-1,2,4-oxadiazol-5-yl)benzyl)carbamate, which was then subjected to general procedure K to give the corresponding HCl salt, which was subsequently coupled to 4-fluoro-1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G2 to afford the title compound as a white solid (31%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$):

δ 8.82 (s, 1H), 8.07 (d, J = 8.2 Hz, 2H), 7.57 (dd, J = 8.0 Hz, 3H), 4.55 (d, J = 5.6 Hz, 2H), 3.95 (s, 3H), 2.78 (q, J = 7.4, 2H), 1.28 (t, J = 7.4 Hz, 3H). LC-MS: m/z = 328 $[\text{M} - \text{H}]^+$.

2-(4-(5-Ethyl-1,2,4-oxadiazol-3-yl)phenyl)-N-(1-methyl-1H-pyrazol-5-yl)acetamide (62) (Exp1). General procedure G1 was followed, starting from 2-(4-cyanophenyl)acetic acid and 1-methyl-1H-pyrazol-5-amine to give 2-(4-cyanophenyl)-N-(1-methyl-1H-pyrazol-5-yl)acetamide, which was subjected to general procedure H to form the amidoxime, then general procedure J2 with propionic acid to give the title compound as a white solid (34%). ^1H NMR (400 MHz, CDCl_3) δ = 8.11 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 1.6 Hz, 1H), 7.14 (s, br, 1H), 6.18 (d, J = 1.8 Hz, 1H), 3.82 (s, J = 9.9 Hz, 2H), 3.59 (s, 3H), 2.98 (q, J = 7.6 Hz, 2H), 1.46 (t, J = 7.6 Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 168.8, 167.8, 167.2, 138.4, 137.0, 130.0, 128.4, 126.8, 102.8, 100.5, 43.7, 35.6, 20.4, 10.9 ppm. LC-MS: m/z = 311.9 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-fluorobenzyl)-4-fluoro-1-methyl-1H-pyrazole-5-carboxamide (63) (Exp2). General procedure K was followed, starting from **111**, to give the desired free base, which was subsequently coupled to 4-fluoro-1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G2 to afford the title compound as an off-white solid (25%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.77 (t, J = 5.8 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.73 (d, J = 10.7 Hz, 1H), 7.60 (d, J = 4.3 Hz, 1H), 7.58–7.54 (m, 1H), 4.57 (d, J = 5.8 Hz, 2H), 3.95 (s, 3H), 3.02 (q, J = 7.4 Hz, 2H), 1.34 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 348.2 $[\text{M} + \text{H}]^+$.

N-(4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-3-fluorobenzyl)-4-fluoro-1-methyl-1H-pyrazole-5-carboxamide (64) (Exp2). General procedure K was followed, starting from **113**, to give the desired free base, which was subsequently coupled to 4-fluoro-1-methyl-1H-pyrazole-5-carboxylic acid according to general procedure G2 to afford the title compound as an off-white solid (40%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.81 (t, J = 5.9 Hz, 1H), 7.98 (t, J = 7.6 Hz, 1H), 7.61 (d, J = 4.3 Hz, 1H), 7.38–7.34 (m, 2H), 4.55 (d, J = 5.9 Hz, 2H), 3.95 (s, 3H), 3.02 (q, J = 7.6 Hz, 2H), 1.34 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 348.2 $[\text{M} + \text{H}]^+$.

4-(4-Methylthiazol-2-yl)benzonitrile (65) (Exp1). Title compound was prepared according to general procedure A1, starting from 2-bromo-4-methylthiazole and (4-cyanophenyl)boronic acid, to give a yellow solid (76%). ^1H NMR (400 MHz, CDCl_3) δ = 8.02 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 6.98 (s, 1H), 2.51 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 164.9, 154.8, 137.6, 132.7, 126.8, 118.5, 115.4, 113.0, 17.2 ppm. LC-MS: m/z = 201.1 $[\text{M} + \text{H}]^+$.

(4-(4-Methylthiazol-2-yl)phenyl)methanamine HCl (66) (Exp1). Title compound was prepared according to general procedure B1, starting from **65**, to give a yellow solid (98%). ^1H NMR (400 MHz, DMSO) δ = 8.65 (s, br, 3H), 7.95 (d, J = 8.3 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 0.9 Hz, 1H), 4.05 (q, J = 5.6 Hz, 2H), 2.43 (d, J = 0.7 Hz, 3H) ppm. ^{13}C NMR (101 MHz, DMSO) δ = 165.7, 153.0, 136.0, 132.8, 129.8, 126.0, 115.1, 66.3, 16.7 ppm. LC-MS: m/z = 205.1 $[\text{M} + \text{H}]^+$.

4-Ethyl-1,3-thiazol-2-amine (67) (Exp2). Title compound was prepared according to general procedure D1, starting from 1-bromo-2-butanone and thiourea, to give a gummy liquid (82%), which was used in next step without purification. ^1H NMR (400 MHz, CDCl_3): δ = 6.06 (s, 1H), 5.10 (br, 2H), 2.55 (q, J = 7.6 Hz, 2H), 1.22 (t, J = 7.4 Hz, 3H) ppm. LC-MS: m/z = 129.0 $[\text{M} + \text{H}]^+$.

2-Bromo-4-ethyl-1,3-thiazole (68) (Exp2). Title compound was prepared according to general procedure E1, starting from **67**, to give a brown gummy liquid (40%). ^1H NMR (400 MHz, CDCl_3): δ = 6.82 (s, 1H), 2.77 (q, J = 7.2 Hz, 2H), 1.26 (t, J = 7.4 Hz, 3H) ppm. LC-MS: m/z = 192 $[\text{M}]^+$, 194 $[\text{M} + 2]^+$.

4-(4-Ethyl-1,3-thiazol-2-yl)benzonitrile (69) (Exp2). Title compound was prepared according to general procedure A2, starting from **68** and (4-cyanophenyl)boronic acid, to give a pale-yellow solid (51%). ^1H NMR (400 MHz, CDCl_3): δ = 8.04 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 6.99 (s, 1H), 2.90–2.82 (m, 2H), 1.34 (t, J = 7.60 Hz, 3H) ppm. LC-MS: m/z = 215.0 $[\text{M} + \text{H}]^+$.

(4-(4-Ethylthiazol-2-yl)phenyl)methanamine (70) (Exp2). Title compound was prepared according to general procedure B2,

starting from **69**, to give a pale-yellow solid (86%). ^1H NMR (400 MHz, CDCl_3): δ = 7.89 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 6.85 (s, 1H), 3.90 (s, 2H), 2.85 (q, J = 7.4 Hz, 2H), 1.33 (t, J = 7.4 Hz, 3H) ppm. LC-MS: m/z = 219.0 $[\text{M} + \text{H}]^+$.

Dimethyl 1H-Pyrazole-3,5-dicarboxylate (71) (Exp2). To a stirred solution of 1H-pyrazole-3,5-dicarboxylic acid (3.5 g, 22.43 mmol) in EtOH (84 mL) was added SOCl_2 (14 mL) at 0 °C. The reaction mixture was stirred at room temperature for 18 h. Upon completion, the reaction was concentrated in vacuo to afford title compound (3.5 g, 85%) as an off-white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.34 (s, 1H), 3.95 (s, 6H) ppm. LCMS m/z = 185.0 $[\text{M} + \text{H}]^+$.

Dimethyl 1-Methyl-1H-pyrazole-3,5-dicarboxylate (72) (Exp2). To a stirred solution of **71** (3.5 g, 19.02 mmol) and K_2CO_3 (3.94 g, 28.53 mmol) in acetone (100 mL) at room temperature, dimethyl sulphate (2 mL, 20.92 mmol) was added. The reaction mixture was stirred at 40 °C for 3 h. After completion, the reaction mixture was filtered and filtrate was concentrated in vacuo to afford title compound (3.5 g, 93%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.34 (s, 1H), 4.24 (s, 3H), 3.92 (s, 3H), 3.89 (s, 3H) ppm. LCMS m/z = 199 $[\text{M} + \text{H}]^+$.

5-(Methoxycarbonyl)-1-methyl-1H-pyrazole-3-carboxylic acid (73) (Exp2). To a stirred solution of **72** (4 g, 20.20 mmol) in 1,4-dioxane (16 mL) and water (40 mL), concentrated H_2SO_4 (0.43 mL, 8.081 mmol) was added dropwise. The reaction mixture was refluxed for 24 h. Upon completion, the reaction mixture was concentrated in vacuo to afford a gummy liquid, which was dissolved in CHCl_3 and filtered. Filtrate was concentrated to afford title compound (1.2 g, 32%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.40 (s, 1H), 4.27 (s, 3H), 3.91 (s, 3H) ppm. LCMS m/z = 185.0 $[\text{M} + \text{H}]^+$.

Methyl-3-carbamoyl-1-methyl-1H-pyrazole-5-carboxylate (74) (Exp2). A mixture of **73** (1.2 g, 4.22 mmol) and SOCl_2 (10 mL) was stirred at 80 °C for 2 h. The reaction mixture was concentrated, diluted with toluene (10 mL), and ammonia gas was passed into the reaction mixture at 0 °C for 2 h. After completion, the reaction mixture was quenched by the addition of cold water and extracted with 10% MeOH in DCM, dried over anhydrous Na_2SO_4 , and concentrated to give title compound (0.92 g, 77%) as an off-white solid which was used in next step without purification. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.68 (s, 1H), 7.38 (s, 1H), 7.18 (s, 1H), 4.12 (s, 3H), 3.85 (s, 3H) ppm. LC-MS: m/z = 184 $[\text{M} + \text{H}]^+$.

Methyl-3-cyano-1-methyl-1H-pyrazole-5-carboxylate (75) (Exp2). To a stirred solution of **74** (0.90 g, 4.89 mmol) in DCM (15 mL) was added DIPEA (2.3 mL, 13.21 mmol) at 0 °C. A solution of trifluoroacetic anhydride (0.78 mL, 5.63 mmol) in DCM (5 mL) was then added at 0 °C. The reaction mixture was stirred at 0 °C for 2 h then diluted with DCM. The organic layer was washed with saturated NaHCO_3 solution, 5% citric acid solution and brine, dried over Na_2SO_4 , and concentrated in vacuo to afford a gummy liquid, which was purified by column chromatography (10% EtOAc in hexane) to afford title compound (0.80 g, 99%) as off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.61 (s, 1H), 4.17 (s, 3H), 3.87 (s, 3H) ppm. LC-MS: m/z = 166 $[\text{M} + \text{H}]^+$.

3-Cyano-1-methyl-1H-pyrazole-5-carboxylic acid (76) (Exp2). Title compound was prepared according to general procedure F1, starting from **75** to give an off-white solid (37%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 14.02 (br s, 1H), 7.52 (s, 1H), 4.16 (s, 3H) ppm. LC-MS: m/z = 149.9 $[\text{M} - \text{H}]^+$.

Methyl 4-fluoro-1-methyl-1H-pyrazole-5-carboxylate (77) (Exp1). To a solution of methyl 1-methyl-1H-pyrazole-5-carboxylate (0.5 g) in ACN (7 mL) and acetic acid (1.0 mL) was added Selectfluor (1.37 g). The mixture was heated at 100 °C under microwave irradiation for 120 min. Selectfluor (1.37 g) was added to the mixture and heated at 100 °C under microwave irradiation for 60 min. The solvent was removed in vacuo (water bath was kept at room temperature to avoid loss of product under vacuum as product is very volatile), and the residue was partitioned between DCM (15 mL) and water (25 mL). The aqueous layer was further extracted with DCM (2 $\times$ 10 mL), and the combined organic layers

concentrated in vacuo (water bath was kept at room temperature to avoid loss of product under vacuum as product is very volatile). The crude product was purified by flash chromatography column on silica gel, eluting with a gradient of 0–15% EtOAc/petroleum benzene to give the title compound as a white solid (0.17 g, 31%). ^1H NMR (400 MHz, CDCl_3): δ = 7.36 (d, J = 4.4 Hz, 1H), 4.13 (d, J = 1.0 Hz, 3H), 3.95 (s, 3H). ^{19}F NMR (376 MHz, CDCl_3): δ = -161.3 (s) ppm. LC-MS: R_t 2.89 min, does not ionize.

1-Methyl-4-fluoro-1H-pyrazole-5-carboxylic Acid (78) (Exp1). Title compound was prepared according to general procedure F2, starting from **77**, to give a white solid (95% yield). ^1H NMR (400 MHz, MeOD) δ 7.40 (d, J = 4.2 Hz, 1H), 4.06 (d, J = 0.7 Hz, 3H). LC-MS R_t 1.17 min, does not ionize.

1-Methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-pyrazole-5-carboxamide (79) (Exp1). Title compound was prepared according to general procedure G1, starting from (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine and 1-methyl-1H-pyrazole-5-carboxylic acid, to give a white solid (74%). ^1H NMR (400 MHz, CDCl_3): δ = 7.77 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 2.1 Hz, 1H), 7.29 (t, J = 8.1 Hz, 2H), 6.59 (s, br, 1H), 6.50 (d, J = 2.1 Hz, 1H), 4.56 (d, J = 5.8 Hz, 2H), 4.15 (s, 3H), 1.32 (s, 12H) ppm. ^{13}C NMR (101 MHz, CDCl_3): δ = 171.2, 159.9, 140.9, 137.6, 135.3, 135.1, 127.1, 106.4, 83.9, 43.6, 39.3, 24.9 ppm. LC-MS: m/z = 341.9 $[\text{M} + \text{H}]^+$.

2-(4-Bromophenyl)ethanethioamide (80) (Exp2). To a stirred solution of 2-(4-bromophenyl)acetonitrile (0.5 g, 2.55 mmol) in pyridine (7 mL) was added Et_3N (7 mL). The reaction mixture was cooled to 0 °C, and H_2S gas was passed through for 10 min. The reaction mixture was stirred at 50 °C for 16 h, then cooled to room temperature and diluted with EtOAc (20 mL). The organic layer was washed with 1 N HCl solution, water, and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo. The crude product was purified by column chromatography (5% EtOAc in hexane) to afford title compound (0.55 g, 94%) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 9.50 (br s, 1H), 9.38 (br s, 1H), 7.50 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 3.78 (s, 2H) ppm. LC-MS: m/z = 308 $[\text{M} + \text{H}]^+$, 310 $[\text{M} + \text{H}]^+$.

2-(4-Bromobenzyl)-4-methylthiazole (81) (Exp2). Title compound was prepared according to general procedure D1, starting from **80** and chloroacetone to give a gummy liquid (64%). ^1H NMR (400 MHz, CDCl_3): δ = 7.43 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.73 (s, 1H), 4.22 (s, 2H), 2.41 (s, 3H) ppm. LC-MS: m/z = 268 $[\text{M}]^+$, 270 $[\text{M} + 2]^+$.

4-((4-Methylthiazol-2-yl)methyl)benzonitrile (82) (Exp2). Title compound was prepared according to general procedure C, starting from **81** to give a yellow solid (92%). ^1H NMR (400 MHz, CDCl_3): δ = 7.63 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 6.80 (s, 1H), 4.36 (s, 2H), 2.45 (s, 3H) ppm. LC-MS: m/z = 215 $[\text{M} + \text{H}]^+$.

2-(4-Bromophenyl)-4-(trifluoromethyl)-1,3-thiazole (83) (Exp2). Title compound was prepared according to general procedure D2, starting from 4-bromo-thiobenzamide and 3-bromo-1,1,1-trifluoro-propan-2-one, to give an off-white solid (52%). ^1H NMR (400 MHz, CDCl_3): δ = 7.84 (d, J = 8.3 Hz, 2H), 7.74 (s, 1H), 7.59 (d, J = 8.2 Hz, 2H) ppm. LC-MS: m/z = 308 $[\text{M}]^+$, 310 $[\text{M} + \text{H}]^+$.

4-(4-(Trifluoromethyl)thiazol-2-yl)benzonitrile (84) (Exp2). Title compound was prepared according to general procedure C, starting from **83**, to give a yellow solid (0.4 g, 98%). ^1H NMR (400 MHz, CDCl_3): δ = 8.09 (d, J = 8.3 Hz, 2H), 7.84 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H) ppm. LC-MS: m/z = 255.2 $[\text{M} + \text{H}]^+$.

2-Bromo-1,3-thiazole-4-carboxylic acid (85) (Exp2). Title compound was prepared according to general procedure F1, starting from 2-bromo-1,3-thiazole-4-carboxylic acid ethyl ester to give a white solid (91%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 13.31 (s, 1H), 8.46 (s, 1H) ppm. LC-MS: m/z = 207.9 $[\text{M} + \text{H}]^+$, 209.9 $[\text{M} + \text{H}]^+$.

2-Bromo-N-methoxy-N-methyl-1,3-thiazole-4-carboxamide (86) (Exp2). Title compound was prepared according to general procedure G2, starting from **85** and *N,O*-dimethylhydroxylamine

HCl, to give a brown gum (66%). ^1H NMR (400 MHz, CDCl_3): δ = 7.95 (s, 1H), 3.77 (s, 3H), 3.40 (s, 3H) ppm. LC-MS: m/z = 251.1 $[\text{M} + \text{H}]^+$, 253.1 $[\text{M} + \text{H}]^+$.

1-(2-Bromo-1,3-thiazol-4-yl)ethan-1-one (87) (Exp2). To a stirred solution of **86** (6 g, 23.9 mmol) in THF (25 mL) was added CH_3MgBr (8 mL, 3 M in THF) dropwise at 0 °C. Reaction mixture was stirred at 0 °C for 1 h. After completion of reaction, the reaction mixture was quenched by the addition of saturated NH_4Cl solution. Aqueous layer was extracted with EtOAc (3 $\times$ 20 mL), and the combined organic layer was washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo. Crude product was purified by column chromatography (5% EtOAc in hexane) to afford title compound (0.6 g, 12%) as white solid. ^1H NMR (400 MHz, CDCl_3): δ = 8.06 (s, 1H), 2.64 (s, 3H) ppm. LC-MS: m/z = 206.2 $[\text{M} + \text{H}]^+$, 208.2 $[\text{M} + \text{H}]^+$.

2-Bromo-4-(1,1-difluoroethyl)-1,3-thiazole (88) (Exp2). To a solution of **87** (600 mg, 2.91 mmol) in DCE (7 mL) was added DAST (3.8 mL, 29.13 mmol). The mixture was taken in a sealed tube and heated at 80 °C for 48 h. Upon completion, reaction mixture was cooled to room temperature and quenched with solid Na_2CO_3 , followed by ice water. Aqueous layer was extracted with EtOAc (3 $\times$ 10 mL). The combined organic layer was washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo. The crude product was purified by column chromatography (5% EtOAc in hexane) to afford title compound (350 mg, 53%) as brown oil. ^1H NMR (400 MHz, CDCl_3): δ = 7.50 (s, 1H), 2.00 (t, J = 18.4 Hz, 3H) ppm. LC-MS: m/z = 228.2 $[\text{M} + \text{H}]^+$, 230.1 $[\text{M} + \text{H}]^+$.

4-(4-(1,1-Difluoroethyl)thiazol-2-yl)benzonitrile (89) (Exp2). Title compound was prepared according to general procedure A3, starting from **88** and (4-cyanophenyl)boronic acid, to give a white solid (57%). ^1H NMR (400 MHz, CDCl_3): δ = 8.08 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.65 (s, 1H), 2.08 (t, J = 18.4 Hz, 3H) ppm. LC-MS: m/z = 251.3 $[\text{M} + \text{H}]^+$.

4-(4-(1,1-Difluoroethyl)thiazol-2-yl)phenylmethanamine (90) (Exp2). Title compound was prepared according to general procedure B2, starting from **89**, to give a white solid (89%). ^1H NMR (400 MHz, CDCl_3): δ = 7.92 (d, J = 8.1 Hz, 2H), 7.51 (s, 1H), 7.39 (d, J = 8.0 Hz, 2H), 3.92 (s, 2H), 2.07 (t, J = 18.4 Hz, 3H) ppm. LC-MS: m/z = 255.3 $[\text{M} + \text{H}]^+$.

1-Ethyl-3-nitro-1H-pyrazole (91) (Exp2). NaH (60% dispersion in mineral oil) (1.3 g, 34.07 mmol) was added portionwise to a solution of 3-nitro-1H-pyrazole (3.5 g, 30.97 mmol) in dry DMF (30 mL) under argon. The reaction mixture was stirred for 5 min, and then ethyl iodide (2.9 mL, 37.16 mmol) was added dropwise and stirred to 80 °C for 3 h. Upon completion, reaction mixture was cooled to room temperature and neutralized with saturated NaHCO_3 solution. The aqueous layer was extracted with EtOAc (3 $\times$ 10 mL), and the combined organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo. The crude product was purified by column chromatography (30% EtOAc in hexane) to afford title compound (3.25 g, 74%) as a brown oil. ^1H NMR (400 MHz, CDCl_3): δ = 7.45 (d, J = 2.0 Hz, 1H), 6.88 (d, J = 7.3 Hz, 1H), 4.25 (q, J = 7.3 Hz, 2H), 1.55 (t, J = 7.3 Hz, 3H) ppm. LC-MS: m/z = 142.1 $[\text{M} + \text{H}]^+$.

1-Ethyl-1H-pyrazol-3-amine (92) (Exp2). A stirred solution of **91** (2 g, 14.18 mmol) in MeOH (20 mL) was degassed under N_2 for 5 min. Then Pd/C (10%) (0.15 g) was added portionwise to the reaction mixture and stirred under H_2 balloon for 5 h. Upon completion, the reaction mixture was filtered through a pad of Celite and washed thoroughly with MeOH. The filtrate was concentrated in vacuo to afford title compound (1.4 g, 89%) as brown liquid. ^1H NMR (400 MHz, CDCl_3): δ = 7.10 (d, J = 1.2 Hz, 1H), 5.49 (d, J = 1.4 Hz, 1H), 3.94 (q, J = 7.2 Hz, 2H), 3.58 (br, 2H), 1.39 (t, J = 7.2 Hz, 3H) ppm. LC-MS: m/z = 112 $[\text{M} + \text{H}]^+$.

3-Bromo-1-ethyl-1H-pyrazole (93) (Exp2). Title compound was prepared according to general procedure E2, starting from **92**, to give a brown liquid (25%). ^1H NMR (400 MHz, CDCl_3): δ = 7.21 (d, J = 1.6 Hz, 1H), 6.23 (d, J = 1.6 Hz, 1H), 4.12 (q, J = 7.3 Hz, 2H), 1.47 (t, J = 7.2 Hz, 3H) ppm. LC-MS: m/z = 175.2 $[\text{M} + \text{H}]^+$, 177.2 $[\text{M} + \text{H}]^+$ (1:1 bromo pattern).

4-(1-Ethyl-1H-pyrazol-3-yl)benzonitrile (94) (Exp2). Title compound was prepared according to general procedure A4, starting from **93** and (4-cyanophenyl)boronic acid, to give a yellow solid (36%). ^1H NMR (400 MHz, CDCl_3): δ = 7.88 (d, J = 8.1 Hz, 2H), 7.65 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 1.5 Hz, 1H), 6.58 (d, J = 1.5 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 1.54 (t, J = 7.4 Hz, 3H) ppm. LC-MS: m/z = 198.3 $[\text{M} + \text{H}]^+$.

4-(4-Ethyl-2H-1,2,3-triazol-2-yl)benzonitrile (95) (Exp2). To a solution of trimethylsilyl azide (2 g, 17.40 mmol) in a 9:1 mixture of DMF:MeOH (20 mL) in a sealed tube was added CuI (0.17 g, 0.87 mmol). Butyne gas was purged through the reaction mixture for 15 min at 0 °C. The reaction mixture was then stirred at 70 °C for 6 h, then cooled to room temperature and diluted with EtOAc, washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo to afford 4-ethyl-1H-1,2,3-triazole, which was then reacted with 4-fluorobenzonitrile (0.62 g, 5.15 mmol) in DMF (7 mL) and K_2CO_3 (1.42 g, 10.31 mmol) at 100 °C for 8 h. Upon completion, reaction mixture was diluted with EtOAc, washed with water and brine, dried (Na_2SO_4), and concentrated in vacuo. Crude product was purified by column chromatography (20% EtOAc in hexane) to afford title compound (0.6 g, 59%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 8.15 (dd, J = 7.0, 1.7 Hz, 2H), 7.76–7.73 (m, 2H), 7.64 (s, 1H), 2.79 (q, J = 7.6 Hz, 2H), 1.32 (t, J = 7.6 Hz, 3H) ppm. LC-MS: m/z = 199.1 $[\text{M} + \text{H}]^+$.

5-(4-Bromophenyl)-3-ethyl-1H-1,2,4-triazole (96) (Exp2). To a mixture of 4-bromobenzonitrile (1.1 g, 6.15 mmol) and propionamidine HCl (1.0 g, 9.23 mmol) in DMSO (10 mL) was added Cs_2CO_3 (6 g, 18.50 mmol), followed by CuBr (0.04 g, 0.308 mmol). The reaction mixture was stirred at 120 °C overnight then cooled to room temperature and diluted with EtOAc, washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo. Crude product was purified by column chromatography (50% EtOAc in hexane) to afford title compound (34%) as a brown solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.93 (d, J = 7.9 Hz, 2H), 7.56 (d, J = 7.1 Hz, 2H), 2.88 (q, J = 7.3 Hz, 2H), 1.40 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 252.0 $[\text{M} + \text{H}]^+$, 254.0 $[\text{M} + \text{H}]^+$ (1:1 bromo pattern).

4-(3-Ethyl-1H-1,2,4-triazol-5-yl)benzonitrile (97) (Exp2). Title compound was prepared according to general procedure C, starting from **96**, to give a white solid (76%). ^1H NMR (400 MHz, CDCl_3): δ = 10.60 (br s, 1H), 8.19 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.8 Hz, 2H), 2.95–2.88 (m, 2H), 1.41 (t, J = 7.5 Hz, 3H) ppm. LC-MS: m/z = 199.1 $[\text{M} + \text{H}]^+$.

4-(3-Ethyl-1H-1,2,4-triazol-5-yl)phenylmethanamine (98) (Exp2). Title compound was prepared according to general procedure B2, starting from **97**, to give a yellow gum (80%). ^1H NMR (400 MHz, CDCl_3): δ = 7.99 (d, J = 7.3 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 3.60 (t, J = 6.6 Hz, 2H), 2.87 (q, J = 7.6 Hz, 2H), 0.93 (t, J = 7.3 Hz, 3H) ppm. LC-MS: m/z = 203.1 $[\text{M} + \text{H}]^+$.

N-(4-Cyanobenzyl)-1-methyl-1H-pyrazole-5-carboxamide (99) (Exp2). Title compound was prepared according to general procedure G2, starting from 4-aminomethyl-benzonitrile and 1-methyl-1H-pyrazole-5-carboxylic acid to give a white solid (55%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 9.10 (t, J = 5.8 Hz, 1H), 7.81 (d, J = 7.7 Hz, 2H), 7.50–7.47 (m, 3H), 6.91 (s, 1H), 4.51 (d, J = 5.8 Hz, 2H), 4.04 (s, 3H). LC-MS: m/z = 241.1 $[\text{M} + \text{H}]^+$.

Ethyl 4-((1-Methyl-1H-pyrazole-5-carboxamido)methyl)-benzimidate HCl (100) (Exp2). A stirred solution of **99** (0.35 g, 1.46 mmol) in EtOH (8.0 mL) was cooled to 0 °C, and HCl gas was passed through over 45 min. The reaction mixture was stirred at room temperature for 30 min, then concentrated in vacuo. The crude product was washed with diethyl ether (2 $\times$ 20 mL) to afford title compound (0.22 g, 89%) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 11.99 (br s, 1H), 11.4 (br s, 1H), 9.23 (t, J = 5.9 Hz, 1H), 8.07 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 1.2 Hz, 1H), 6.96 (d, J = 1.3 Hz, 1H), 4.62 (q, J = 6.9 Hz, 2H), 4.54 (d, J = 5.8 Hz, 2H), 4.04 (s, 3H), 1.47 (t, J = 6.8 Hz, 3H) ppm. LC-MS: m/z = 287.2 $[\text{M} + \text{H}]^+$.

N-(4-(N'-Hydroxycarbamimidoyl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (101) (Exp2). Title compound was prepared

according to general procedure H, starting from **99** to give a white solid (47%), which was taken for next step without purification. ^1H NMR (400 MHz, CDCl_3): δ 9.58 (s, 1H), 9.02 (t, J = 6.0 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 1.9 Hz, 1H), 7.29 (d, J = 8.2 Hz, 2H), 6.90 (d, J = 1.9 Hz, 1H), 5.78 (s, 2H), 4.44 (d, J = 6.0 Hz, 2H), 4.06 (s, 3H) ppm. LC-MS: m/z = 274.1 $[\text{M} + \text{H}]^+$.

4-(((tert-Butoxycarbonyl)amino)methyl)benzoic Acid (102) (Exp2). Title compound was prepared according to general procedure I1, starting from 4-aminomethyl-benzoic acid, to give a white solid (1.8 g, 39%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 12.78 (br s, 1H), 7.89 (d, J = 7.8 Hz, 2H), 7.47 (t, J = 5.4 Hz, 1H), 7.33 (d, J = 7.7 Hz, 2H), 4.18 (d, J = 5.4 Hz, 2H), 1.39 (s, 9H) ppm. LC-MS: m/z = 252 $[\text{M} + \text{H}]^+$.

N-Hydroxypropionimidamide (103) (Exp2). Title compound was prepared according to general procedure H, starting from propionitrile, to give a pale-yellow liquid (87%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.72 (s, 1H), 5.28 (s, 2H), 1.99–1.93 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H) ppm. LCMS: m/z = 89 $[\text{M} + \text{H}]^+$.

(2-Fluoro-4-(4-methylthiazol-2-yl)phenyl)methanamine HCl (104) (Exp2). General procedure A3 was followed, starting from 2-bromo-4-methylthiazole and (4-cyano-3-fluorophenyl)boronic acid, to give 2-fluoro-4-(4-methyl-1,3-thiazol-2-yl)benzonitrile, which was subjected to general procedure B3 to give the title compound as white solid (80%). ^1H NMR (400 MHz, CDCl_3): δ 8.55 (br, 3H), 7.83–7.77 (m, 2H), 7.73–7.69 (m, 1H), 7.43 (s, 1H), 4.11–4.07 (m, 2H), 2.40 (s, 3H) ppm. LCMS m/z = 223.1 $[\text{M} + \text{H}]^+$.

5-(4-Methylthiazol-2-yl)picolinonitrile (105) (Exp2). Title compound was prepared according to general procedure A5, starting from 5-bromopicolinonitrile, to give title compound as a white solid (88%). ^1H NMR (400 MHz, CDCl_3): δ 9.22 (d, J = 1.8 Hz, 1H), 8.35 (dd, J = 8.1, 2.0 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.07 (s, 1H), 2.54 (s, 3H) ppm. LC-MS: m/z = 202.3 $[\text{M} + \text{H}]^+$.

(3-Fluoro-4-(4-methylthiazol-2-yl)phenyl)methanamine (106) (Exp2). To a stirring solution of 3-fluoro-4-iodo-benzonitrile (2.5 g, 10.12 mmol) in a mixture of THF (20 mL) and diethyl ether (20 mL), $i\text{PrMgCl}$ (6 mL, 2 M in diethyl ether) was added dropwise at -78°C under N_2 . The mixture was stirred at -78°C for another 1.5 h before triisopropyl borate (3.74 mL, 16.19 mmol) was added dropwise. The mixture was then stirred at -78°C for 15 min then allowed to warm to room temperature. After 3 h at room temperature, 2 M HCl was added and the reaction mixture was stirred at room temperature for 20 min. The reaction mixture was diluted with water, extracted with EtOAc, and the combined organic layer washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated to afford the 4-(dihydroxyboranyl)-3-fluorobenzonitrile, which was directly subjected to a Suzuki coupling reaction according to general procedure A3 to give 3-fluoro-4-(4-methylthiazol-2-yl)benzonitrile, which was then subjected to general procedure B2 to give the title compound as a colorless oil (32%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.11 (t, J = 7.9 Hz, 1H), 7.42 (s, 1H), 7.39–7.36 (m, 1H), 7.29 (d, J = 7.9 Hz, 1H), 3.77 (s, 2H), 2.45 (s, 3H) ppm. LC-MS: m/z = 223.0 $[\text{M} + \text{H}]^+$.

6-(4-Methylthiazol-2-yl)nicotinonitrile (107) (Exp2). A mixture of 5-bromopicolinonitrile (50 mg, 0.27 mmol), $(\text{NH}_4)_2\text{S}$ (0.02 mL, 0.3 mmol), and Et_3N (0.04 mL, 0.3 mmol) in pyridine (1 mL) was stirred at 50°C for 4 h. Upon completion, the reaction mixture was cooled and extracted with EtOAc (3 $\times$ 10 mL). The combined organic layer was washed with water and brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo to give 5-bromopyridine-2-carbothioamide, which was directly subjected to cyclization according to general procedure D1 to give 2-(5-bromopyridin-2-yl)-4-methylthiazole, which was then subjected to general procedure C to give title compound as a brown solid (54%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.83 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.03 (dd, J = 8.3, 1.7 Hz, 1H), 7.12 (s, 1H), 2.53 (s, 3H) ppm. LC-MS: m/z = 202.2 $[\text{M} + \text{H}]^+$.

N-(4-Cyanobenzyl)-4-fluoro-1-methyl-1H-pyrazole-5-carboxamide (108) (Exp2). Title compound was prepared according to general procedure G2, starting from 4-(aminomethyl)benzonitrile and 4-fluoro-1-methyl-1H-pyrazole-5-carboxylic acid to give a color-

less liquid (97%). ^1H NMR (400 MHz, CDCl_3): δ = 7.63 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 4.9 Hz, 1H), 4.66 (d, J = 6.0 Hz, 2H), 4.14 (s, 3H) ppm. LC-MS: m/z = 259.2 $[\text{M} + \text{H}]^+$.

4-Fluoro-N-(4-(N'-hydroxycarbamidoyl)benzyl)-1-methyl-1H-pyrazole-5-carboxamide (109) (Exp2). Title compound was prepared according to general procedure H, starting from **108**, to give a yellow gum (69%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 9.59 (s, 1H), 8.74 (br s, 1H), 7.64–7.58 (m, 3H), 7.30 (d, J = 7.9 Hz, 2H), 5.78 (s, 2H), 4.46 (d, J = 5.7 Hz, 2H), 3.94 (s, 3H) ppm. LC-MS: m/z = 292.2 $[\text{M} + \text{H}]^+$.

tert-Butyl (4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-fluorobenzyl)carbamate (110) (Exp2). General procedure L was followed, starting from 3-fluoro-4-methylbenzonitrile, to afford 4-(bromomethyl)-3-fluorobenzonitrile as a colorless oil, which was then converted to the desired benzylamine according to general procedure M. The resulting benzylamine was subsequently protected according to general procedure I2 to give an off-white solid (45%). ^1H NMR (400 MHz, CDCl_3): δ 7.50–7.40 (m, 2H), 7.35–7.30 (m, 1H), 5.00 (s, 1H), 4.39 (s, 2H), 1.45 (s, 9H) ppm. LCMS: m/z = 195.2 $[\text{M} + \text{H}]^+$.

tert-Butyl (4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-fluorobenzyl)carbamate (111) (Exp2). General procedure H was followed, starting from **110**, to give the desired amidoxime, which was then subjected to general procedure J1 with propionic acid to give the title compound as a white solid (53%). ^1H NMR (400 MHz, CDCl_3): δ 7.83 (d, J = 7.3 Hz, 1H), 7.75 (d, J = 10.2 Hz, 1H), 7.44 (br s, 1H), 4.93 (s, 1H), 4.40 (s, 2H), 2.96 (q, J = 6.7 Hz, 2H), 1.46–1.44 (m, 12H) ppm. LCMS: m/z = 322.4 $[\text{M} + \text{H}]^+$.

tert-Butyl (4-Cyano-3-fluorobenzyl)carbamate (112) (Exp2). General procedure L was followed, starting from 2-fluoro-4-methylbenzonitrile, to afford 4-(bromomethyl)-2-fluorobenzonitrile as a colorless oil, which was then converted to the desired benzylamine according to general procedure M. The resulting benzylamine was subsequently protected according to general procedure I2 to give an off-white solid (68%). ^1H NMR (400 MHz, CDCl_3): δ 7.57 (t, J = 6.8 Hz, 1H), 7.17–7.12 (m, 2H), 4.98 (br s, 1H), 4.35 (d, J = 4.8 Hz, 2H), 1.45 (s, 9H) ppm. LCMS: m/z = 251.4 $[\text{M} + \text{H}]^+$.

tert-Butyl (4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-3-fluorobenzyl)carbamate (113) (Exp2). General procedure H was followed, starting from **112** to give the desired amidoxime, which was then subjected to general procedure J1 with propionic acid, to give the title compound as a white solid (21%). ^1H NMR (400 MHz, CDCl_3): δ 8.00 (t, J = 7.6 Hz, 1H), 7.18–7.13 (m, 2H), 4.95 (br, 1H), 4.36 (d, J = 5.3 Hz, 2H), 2.98 (q, J = 7.6 Hz, 2H), 1.48 (t, J = 7.7 Hz, 3H), 1.38 (s, 9H) ppm. LCMS: m/z = 321.9 $[\text{M} + \text{H}]^+$.

Interference Compounds. All final compounds have been examined for the presence of substructures classified as pan assay interference compounds (PAINS) using a KNIME workflow.^{28,29}

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.8b01544.

Initial SAR from mining the HTS deck (PDF)

SMILES molecular formula strings (CSV)

■ AUTHOR INFORMATION

Corresponding Authors

*For J.B.B.: phone, +61 3 9903 9044; E-mail, Jonathan.Baell@monash.edu.

*For R.B.G.: phone, +61 3 9731 2283; E-mail, robinbg@unimelb.edu.au.

ORCID

Jennifer Keiser: 0000-0003-0290-3521

Andreas Hofmann: 0000-0003-4408-5467

Jonathan B. Baell: 0000-0003-2114-8242

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Support from the Australian Research Council (ARC), Medicines for Malaria Venture (MMV), and Yougene Bioscience is gratefully acknowledged. Fellowship support (J.B.) was from the National Health and Medical Research Council of Australia (NHMRC) (2012–2016 Senior Research Fellowship no. 1020411, Principle Research Fellowship no. 1117602). Also acknowledged is Australian Federal Government Education Investment Fund Super Science Initiative and the Victorian State Government, Victoria Science Agenda Investment Fund, for infrastructure support and the facilities, and the scientific and technical assistance of the Australian Translational Medicinal Chemistry Facility (ATMCF), Monash Institute of Pharmaceutical Sciences (MIPS). ATMCF is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program. The Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, is acknowledged for their conduct of the ADME screening studies. The Peter McCallum Cancer Centre is acknowledged for their conduct of the cytotoxicity studies.

■ ABBREVIATIONS USED

ACN, acetonitrile; DCM, dichloromethane; HTS, high throughput screen; LHS, left-hand side; RHS, right-hand side

■ REFERENCES

- (1) Anderson, R. C. *Nematode Parasites of Vertebrates: Their Development and Transmission*; Cabi, 2000.
- (2) Roeber, F.; Jex, A. R.; Gasser, R. B. Impact of Gastrointestinal Parasitic Nematodes of Sheep, and the Role of Advanced Molecular Tools for Exploring Epidemiology and Drug Resistance - An Australian Perspective. *Parasites Vectors* **2013**, *6*, 153.
- (3) Knox, M. R.; Besier, R. B.; Le Jambre, L. F.; Kaplan, R. M.; Torres-Acosta, J. F. J.; Miller, J.; Sutherland, I. Novel Approaches for the Control of Helminth Parasites of Livestock VI: Summary of Discussions and Conclusions. *Vet. Parasitol.* **2012**, *186* (1), 143–149.
- (4) Rang, H.; Dale, M. *Rang & Dale's Pharmacology*, 7th ed.; Churchill Livingstone: Edinburgh, 2012.
- (5) Miller, D. K.; Craig, T. M. Use of Anthelmintic Combinations against Multiple Resistant *Haemonchus contortus* in Angora Goats. *Small Rumin. Res.* **1996**, *19* (3), 281–283.
- (6) Van Wyk, J. A.; Malan, F. S.; Randles, J. L. How Long before Resistance Makes It Impossible to Control Some Field Strains of *Haemonchus contortus* in South Africa with Any of the Modern Anthelmintics? *Vet. Parasitol.* **1997**, *70* (1–3), 111–122.
- (7) Kaminsky, R.; Ducray, P.; Jung, M.; Clover, R.; Rufener, L.; Bouvier, J.; Weber, S. S.; Wenger, A.; Wieland-berghausen, S.; Goebel, T.; Gauvry, N.; Pautrat, F.; Skripsky, T.; Froelich, O.; Komoin-Oka, C.; Westlund, B.; Sluder, A.; Mäser, P. A New Class of Anthelmintics Effective against Drug-Resistant Nematodes. *Nature* **2008**, *452* (7184), 176–180.
- (8) Little, P. R.; Hodge, A.; Watson, T. G.; Seed, J. A.; Maeder, S. J. Field Efficacy and Safety of an Oral Formulation of the Novel Combination Anthelmintic, Derquantel-Abamectin, in Sheep in New Zealand. *N. Z. Vet. J.* **2010**, *58* (3), 121–129.
- (9) Van den Brom, R.; Moll, L.; Kappert, C.; Vellema, P. *Haemonchus contortus* Resistance to Monepantel in Sheep. *Vet. Parasitol.* **2015**, *209* (3–4), 278–280.
- (10) Sager, H.; Bapst, B.; Strehlau, G. A.; Kaminsky, R. Efficacy of Monepantel, Derquantel and Abamectin against Adult Stages of a Multi-Resistant *Haemonchus contortus* Isolate. *Parasitol. Res.* **2012**, *111* (5), 2205–2207.
- (11) Gordon, C. P.; Hizartidis, L.; Tarleton, M.; Sakoff, J. A.; Gilbert, J.; Campbell, B. E.; Gasser, R. B.; McCluskey, A. Discovery of Acrylonitrile-Based Small Molecules Active against *Haemonchus contortus*. *MedChemComm* **2014**, *5* (2), 159–164.
- (12) Ali, A.; Cablewski, T.; Francis, C. L.; Ganguly, A. K.; Sargent, R. M.; Sawutz, D. G.; Winzenberg, K. N. 2-Phenylimidazo[1,2-b]pyridazine Derivatives Highly Active against *Haemonchus contortus*. *Bioorg. Med. Chem. Lett.* **2011**, *21* (14), 4160–4163.
- (13) Preston, S.; Luo, J.; Zhang, Y.; Jabbar, A.; Crawford, S.; Baell, J.; Hofmann, A.; Hu, M.; Zhou, H.-B.; Gasser, R. B. Selenophene and Thiophene-Core Estrogen Receptor Ligands That Inhibit Motility and Development of Parasitic Stages of *Haemonchus contortus*. *Parasites Vectors* **2016**, *9* (1), 346–356.
- (14) Preston, S.; Jabbar, A.; Nowell, C.; Joachim, A.; Rutkowski, B.; Baell, J.; Cardno, T.; Korhonen, P. K.; Piedrafita, D.; Ansell, B. R. E.; Jex, A. R.; Hofmann, A.; Gasser, R. B. Low Cost Whole-Organism Screening of Compounds for Anthelmintic Activity. *Int. J. Parasitol.* **2015**, *45* (5), 333–343.
- (15) Preston, S.; Jabbar, A.; Nowell, C.; Joachim, A.; Rutkowski, B.; Cardno, T.; Hofmann, A.; Gasser, R. B. Practical and Low Cost Whole-Organism Motility Assay: A Step-by-Step Protocol. *Mol. Cell. Probes* **2016**, *30* (1), 13–17.
- (16) Preston, S.; Jiao, Y.; Jabbar, A.; McGee, S. L.; Laleu, B.; Willis, P.; Wells, T. N. C.; Gasser, R. B. Screening of the “Pathogen Box” Identifies an Approved Pesticide with Major Anthelmintic Activity against the Barber's Pole Worm. *Int. J. Parasitol.: Drugs Drug Resist.* **2016**, *6* (3), 329–334.
- (17) Jiao, Y.; Preston, S.; Song, H.; Jabbar, A.; Liu, Y.; Baell, J.; Hofmann, A.; Hutchinson, D.; Wang, T.; Koehler, A. V.; Fisher, G. M.; Andrews, K. T.; Laleu, B.; Palmer, M. J.; Burrows, J. N.; Wells, T. N. C.; Wang, Q.; Gasser, R. B. Assessing the Anthelmintic Activity of Pyrazole-5-Carboxamide Derivatives against *Haemonchus contortus*. *Parasites Vectors* **2017**, *10* (1), 272.
- (18) Preston, S.; Jiao, Y.; Baell, J. B.; Keiser, J.; Crawford, S.; Koehler, A. V.; Wang, T.; Simpson, M. M.; Kaplan, R. M.; Cowley, K. J.; Simpson, K. J.; Hofmann, A.; Jabbar, A.; Gasser, R. B. Screening of the ‘Open Scaffolds’ Collection from Compounds Australia Identifies a New Chemical Entity with Anthelmintic Activities against Different Developmental Stages of the Barber's Pole Worm and Other Parasitic Nematodes. *Int. J. Parasitol.: Drugs Drug Resist.* **2017**, *7* (3), 286–294.
- (19) Monroy, F. G.; Enriquez, F. J. Heligmosomoides Polygyrus: A Model for Chronic Gastrointestinal Helminthiasis. *Parasitol. Today* **1992**, *8* (2), 49–54.
- (20) Lipinski, C. A. Lead- and Drug-like Compounds: The Rule-of-Five Revolution. *Drug Discovery Today: Technol.* **2004**, *1* (4), 337–341.
- (21) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *J. Med. Chem.* **2002**, *45* (12), 2615–2623.
- (22) Keiser, J.; Panic, G.; Adelfio, R.; Cowan, N.; Vargas, M.; Scandale, I. Evaluation of an FDA Approved Library against Laboratory Models of Human Intestinal Nematode Infections. *Parasites Vectors* **2016**, *9* (1), 376.
- (23) Bevan, C. D.; Lloyd, R. S. A High-Throughput Screening Method for the Determination of Aqueous Drug Solubility Using Laser Nephelometry in Microtiter Plates. *Anal. Chem.* **2000**, *72* (8), 1781–1787.
- (24) Poulin, P.; Jones, R. D. O.; Jones, H. M.; Gibson, C. R.; Rowland, M.; Chien, J. Y.; Ring, B. J.; Adkison, K. K.; Ku, M. S.; He, H.; Vupputgalla, R.; Marathe, P.; Fischer, V.; Dutta, S.; Sinha, V. K.; Björnsson, T.; Lavé, T.; Yates, J. W. T. PHRMA CPCDC Initiative

on Predictive Models of Human Pharmacokinetics, Part 5: Prediction of Plasma Concentration–time Profiles in Human by Using the Physiologically-based Pharmacokinetic Modeling Approach. *J. Pharm. Sci.* **2011**, *100* (10), 4127–4157.

(25) Obach, R. S. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes. *Drug Metab. Dispos.* **1999**, *27* (11), 1350–1359.

(26) Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. *J. Org. Chem.* **1978**, *43* (14), 2923–2925.

(27) MestReNova; <http://www.mestrelab.com>. Mestrelab Research S.L. Feliciano Barrera 9B, Bajo, 15706 Santiago de Compostela, Spain.

(28) Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. *J. Med. Chem.* **2010**, *53* (7), 2719–2740.

(29) Saubern, S.; Guha, R.; Baell, J. B. KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries. *Mol. Inf.* **2011**, *30* (10), 847–850.